The Role Of Neurokinin Receptors And Satellite Glial Cells In Herpes Simplex Virus 1 Latency by Jerome, Andrew
Wayne State University 
Wayne State University Dissertations 
January 2018 
The Role Of Neurokinin Receptors And Satellite Glial Cells In 
Herpes Simplex Virus 1 Latency 
Andrew Jerome 
Wayne State University, adjerome@med.wayne.edu 
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations 
 Part of the Immunology and Infectious Disease Commons, Neurosciences Commons, and the 
Virology Commons 
Recommended Citation 
Jerome, Andrew, "The Role Of Neurokinin Receptors And Satellite Glial Cells In Herpes Simplex Virus 1 
Latency" (2018). Wayne State University Dissertations. 2032. 
https://digitalcommons.wayne.edu/oa_dissertations/2032 
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has 





THE ROLE OF NEUROKININ RECEPTORS AND SATELLITE GLIAL 





Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
2018 
MAJOR: ANATOMY AND CELL BIOLOGY 
Approved By: 
_____________________________________ 














To my wife, Tori 
And my parents, Dave and Cecilia 






First and foremost, I would like to express my deepest thanks and gratitude to my 
mentor, Dr. Susmit Suvas. As an aspiring scientist, he was willing to give me an 
opportunity for which I am forever grateful. His tremendous mentorship and leadership 
has allowed for me to develop into the scientist I am today, and his infectious curiosity 
and encouragement has continuously inspired me to find new scientific avenues in which 
to explore.  
I would like to thank my committee members, Dr. Elizabeth Berger, Dr. Phil Pellett, 
and Dr. Robert Skoff for their guidance throughout my project. Their feedback and support 
has greatly improved my scientific understanding. I would also like to thank the members 
of the Anatomy and Cell Biology department here at Wayne State. Especially the 
Department Chair, Dr. Linda Hazlett, who has consistently encouraged and supported the 
graduate students.  
I would like to thank the members of the Suvas lab who have helped me along the 
way. To Nick, for his guidance when I first started, and Pushpa who has been a constant 
source of valuable insight and conversation throughout my PhD. I would also like to thank 
Subhash and Bala, for their experimental contributions and in aiding my scientific growth.  
Finally, none of this work would be possible without my family and friends. I would 
like to thank my wife, Tori, for being an ever-calming presence in my life. Her 
encouragement and support is truly exceptional; I couldn’t have done any of this without 
her. I would also like to thank my parents, Dave and Cecilia, who have always encouraged 
me to pursue what makes me happy. And to my friends, who can always be counted on 




TABLE OF CONTENTS 
DEDICATION ...................................................................................................................ii 
ACKNOWLEDGMENTS .................................................................................................. iii 
LIST OF FIGURES ......................................................................................................... vii 
LIST OF TABLES ............................................................................................................ x 
INTRODUCTION ............................................................................................................. 1 
1. Herpes Simplex Virus 1 ......................................................................................... 1 
1.1. Epidemiology .................................................................................................. 1 
1.2. Viral Structure ................................................................................................. 1 
1.3. HSV-1 Lytic Life Cycle .................................................................................... 2 
2. Herpes Simplex Virus 1 Latency ........................................................................... 5 
2.1. HSV-1 Latency Overview ................................................................................ 5 
2.2. The Role of the Immune System in the Establishment of HSV-1 Latency ...... 7 
2.3. The role of the immune system in the maintenance of HSV-1 latency ............ 9 
2.4. Herpes Simplex Virus Encephalitis ............................................................... 11 
3. Neurotrophic factors and Neuropeptides ............................................................. 12 
3.1. Calcitonin Gene Related Peptide .................................................................. 12 
3.2. Somatostatin ................................................................................................. 13 
3.3. Vasoactive Intestinal Peptide ........................................................................ 14 
3.4. Neuropeptide Y and Galanin ......................................................................... 15 
3.5. Substance P ................................................................................................. 16 




4. Localized Cell Response in the TG ..................................................................... 18 
4.1. Anatomy of the TG ........................................................................................ 18 
4.2. Response to pain and inflammation .............................................................. 18 
MATERIALS AND METHODS ...................................................................................... 26 
CHAPTER 1: THE EFFECT OF NEUROKIININ RECEPTOR SIGNALING ON THE 
ESTABLISHMENT OF HSV-1 LATENCY ..................................................................... 39 
Abstract ...................................................................................................................... 39 
Introduction ................................................................................................................ 40 
Results ....................................................................................................................... 42 
Discussion.................................................................................................................. 48 
CHAPTER 2: THE EFFECT OF NEUROKININ RECEPTOR SIGNALING ON THE 
MAINTENANCE OF HSV-1 LATENCY ......................................................................... 65 
Abstract ...................................................................................................................... 65 
Introduction ................................................................................................................ 66 
Results ....................................................................................................................... 67 
Discussion.................................................................................................................. 70 
CHAPTER 3: THE ROLE OF SATELITE GLIAL CELLS IN THE MAINTENANCE OF 
HSV-1 LATENCY .......................................................................................................... 81 
Abstract ...................................................................................................................... 81 
Introduction ................................................................................................................ 82 
Results ....................................................................................................................... 84 
Discussion.................................................................................................................. 90 
GENERAL CONCLUSIONS ........................................................................................ 109 




ABSTRACT ................................................................................................................. 143 






LIST OF FIGURES 
Figure 1: Herpes simplex virus 1 structure. ................................................................... 21 
Figure 2: Herpesvirus Lytic Replication Cycle. .............................................................. 22 
Figure 3: Viral Latency Establishment. .......................................................................... 23 
Figure 4: The human TG. .............................................................................................. 24 
Figure 5: Satellite glial cells surround neurons providing structural and functional support.
 ...................................................................................................................................... 25 
Figure 6: Genotyping of NK1R-/- mice. .......................................................................... 34 
Figure 7: Mouse trigeminal ganglion dissection. ........................................................... 35 
Figure 8: Neuropeptide and neurotrophic factor gene expression in the TG. ................ 52 
Figure 9: Neurokinin receptor expression in the cornea and TG. .................................. 53 
Figure 10: Loss of NK1R signaling leads to increased IFNγ production at day 5 post-
infection. ........................................................................................................................ 54 
Figure 11: NK1R-/- mice lymph nodes express an increase in actively dividing CD4 and 
CD8 T cells at 5 days post-infection. ............................................................................. 55 
Figure 12: Loss of NK1R signaling leads to a larger T cell infiltration in the TG at day 5 
post-infection. ................................................................................................................ 56 
Figure 13: Plasmids for LAT and gB generate a standard curve to determine the 
respective copy numbers of the genes. ......................................................................... 57 
Figure 14: NK1R-/- mice corneas have altered corneal lymphatics that persists up to day 
6 post-infection. ............................................................................................................. 58 
Figure 15: NK1R-/- mice express higher levels of VEGF-C which co-localizes with CD11b.
 ...................................................................................................................................... 59 
Figure 16: Neurokinin receptor antagonist treatment does not affect IFNγ or TNFα 
production by CD8 T cells in the lymph node of 5 day post-infection mice. ................... 60 
Figure 17: Neurokinin receptor antagonist treatment does not affect T cell infiltration into 




Figure 18: L760735 treatment effectively reduces tear production in mice during HSV-1 
infection. ........................................................................................................................ 62 
Figure 19: Neurokinin receptor 2 and 3 expression in the NK1R-/- mice TG. ................. 63 
Figure 20: Loss of NK1R signaling leads to a decreased viral load in the TG at day 10 
post-infection. ................................................................................................................ 64 
Figure 21: Loss of NK1R signaling increases the amount of LAT present in the TG at day 
18 post-infection. ........................................................................................................... 75 
Figure 22: NK1R antagonist treatment in latently infected mice did not produce significant 
changes in LAT copy numbers in the TG. ..................................................................... 76 
Figure 23: Phenotypic changes in VERO cells are used to identify the presence of 
replicating virus in viral reactivation assays. .................................................................. 77 
Figure 24: NK1R antagonist L760735 and NK3R antagonist SB222200 individually delay 
viral reactivation in ex-vivo TG cultures. ........................................................................ 78 
Figure 25: The TGs of latently infected NK1R-/- mice experience delayed viral reactivation 
that does not occur if NK3R antagonist is present in culture media. ............................. 79 
Figure 26: NK1R agonist GR73632 treatment does not lead a change in viral reactivation 
rates in ex-vivo viral reactivation assays. ...................................................................... 80 
Figure 27: There are two actively dividing cell populations in HSV-1 infected TGs. ...... 96 
Figure 28: Satellite glial cells exhibit a distinct immune cell profile. ............................... 97 
Figure 29: Removal of myelin allows for the generation of a clean satellite glial cell 
population. ..................................................................................................................... 98 
Figure 30: SGC population in myelin removed TGs. ..................................................... 99 
Figure 31: Satellite glial cells express NK3R and NK1R at lower levels than neurons in 
naïve TGs. ................................................................................................................... 100 
Figure 32: CD4 and CD8 T cells are present in the TG of latently infected mice. ....... 101 
Figure 33: Ovalbumin specific T cells can be stimulated in-vivo with an antigen presenting 
cell. .............................................................................................................................. 102 
Figure 34: Magnetic removal of F4/80+ cells in infected TGs. .................................... 103 




Figure 36: Antibody Vβ 5.1, 5.2 identifies ovalbumin specific T cells. ......................... 105 
Figure 37: Magnetic CD4 T cell separation contains antigen presenting cells. ........... 106 
Figure 38: Satellite glial cells can act as an antigen presenting cell and induce T cell 
proliferation. ................................................................................................................ 107 






LIST OF TABLES 
Table 1: List of BioRad PrimerPCR Primers used ......................................................... 36 
Table 2: Primer sequences of FAM labeled primers ..................................................... 37 






1. Herpes Simplex Virus 1 
1.1. Epidemiology 
Herpes simplex virus 1 (HSV-1) is an extremely common virus that infects a large 
portion of the world’s population, primarily manifesting as skin lesions commonly known 
as cold sores [1, 2].  Currently, up to 50% of the US population has been identified as 
seropositive for HSV-1, a number that increases to 67% worldwide, and up to 80% in the 
45-49 year-old age group [3, 4].  Due to its ability to lie latent in the trigeminal ganglia 
(TG), HSV-1 is an infection that resides in an individual for life. The number of individuals 
found to be harboring HSV-1 DNA in the TG post-mortem has been reported as up to 
90% [5]. Viral infection primarily occurs via oral contact with an infected individual, and 
the ability of the virus to lie latent permits for the potential of multiple active infections 
throughout an individual’s lifetime [3, 4, 6]. 
While the most common outcome of viral reactivation is herpes labialis (cold 
sores), reactivation can also lead to potentially blinding ocular infections [7, 8]. Ocular 
HSV-1 infection leading to a disease known as herpetic stromal keratitis (HSK) is currently 
the leading cause of virus induced blindness in the United States [7]. HSK occurs due to 
repeated ocular infections leading to epithelial defects and stromal inflammation leading 
to blindness [9]. The primary cause of these repeated corneal infections is recurrent viral 
reactivation of latent virus harbored in the TG [2]. Repeated infections currently make 
ocular HSV-1 very difficult to treat. To date, most cases of ocular HSV-1 are treated with 
a combination of acyclovir and cortical steroids; however, this treatment is not very 
effective in preventing further reactivation events [10-13].  





HSV-1 is a double-stranded DNA virus, with a viral genome contained inside of an 
icosahedral viral capsid, which is further surrounded by an outer tegument, and both the 
capsid and tegument are contained within the viral envelope (Figure 1) [6, 14, 15]. A 
member of the Herpesviridae family, HSV-1 possesses a roughly 152 kbp genome, 
consisting of a unique short (US) region and a unique long (UL) region. Ultimately, nearly 
80 different HSV-1 genes have been identified, which encode over 70 proteins [15-18]. 
HSV-1 genes are further differentiated into three different sets, commonly referred to as 
immediate early (IE), early (E), and late (L) genes [19]. These genes are utilized by the 
virus to replicate through the aid of the host cell [20, 21]. Ultimately, viral propagation 
occurs in three distinct stages: (i) entry of the virus into the host cell, (ii) replication of the 
viral genome in the host cell nucleus, and (iii) egress of newly formed virions from the cell 
[14, 15, 22]. 
1.3. HSV-1 Lytic Life Cycle 
1.3.1. Viral Entry 
The HSV-1 lytic life cycle (Figure 2), or replication of a the virus through the aid of 
host cell machinery, is initiated via attachment of viral glycoproteins on the viral envelope 
to the host cell plasma membrane [6, 23]. To initiate infection, HSV-1 will utilize viral 
envelope glycoproteins gB, gC, gD, gH and gL in the process of virus-host cell fusion and 
viral entry into the host cell  [6, 24-26]. Initially, gB and gC bind to host cell 
glycosaminoglycans (GAG), primarily heparan sulfate, leading to the binding of the viral 
envelope to the host cell [6, 24, 25]. Fusion of the viral envelope to the host cell is then 
initiated by gD, which binds a variety of different host cell receptors including nectin 1 & 





complete envelope-membrane fusion and the viral capsid and tegument proteins will 
enter the host cell, absent the viral envelope [22, 26]. 
Upon entry into the host cell, most of the viral tegument proteins will be released 
into the cytoplasm, where they will perform a number of functions including: the initiation 
of transcription of IE genes by VP16 [28], the inhibition of cellular apoptosis by US3 [29], 
and the direction of the capsid to the nucleus by UL36 [30], among others [31, 32]. The 
viral capsid containing viral DNA is then transported along host cell microtubules via the 
molecular motor protein dynein to the nucleus [14, 33, 34]. These motor proteins will 
transport the capsid (with some tegument proteins still attached) to the nuclear pore 
complex (NPC) of the host cell nuclear membrane [24, 33]. The virus will bind to the NPC 
through multiple nuclear pore proteins, which in turn bind to tegument proteins UL25 and 
UL6 [33]. Finally, after binding, the viral DNA will be injected into the host cell nucleus, 
leaving the viral capsid behind to be degraded by the host cell, and host cell machinery 
will then be utilized in the process of viral replication [33].  
1.3.2. Viral Replication 
Once the viral DNA has reached the nucleus it undergoes a circularization event, 
in which the linear double-stranded DNA becomes a circular DNA molecule [15]. The 
circularized DNA will then be bound by the HSV-1 tegument protein VP16 (also known as 
α-TIF) along with host cell factor-1 (HCF-1), and octamer-binding transcription factor-1 
(Oct-1) at what is known as the TAATGARAT sequence of the HSV-1 genome [28, 35]. 
Binding to the TAATGARAT sequence leads to the transcription of the IE (α) genes. 
Following transcription, the IE mRNA will migrate to the cytoplasm of the infected cell and 





translation, a nuclear localization sequence will guide the IE proteins into the nucleus 
through nuclear pores [16, 35-37] . The immediate effects of these proteins occur via the 
activation of E (β) genes by ICP0 [38, 39], ICP4 [40], and ICP27 [41, 42], among other 
functions. ICP47 however, functions to evade the host immune response through the 
blocking of CD8 T cell recognition. This T cell inhibition is accomplished through binding 
and inhibition of major histocompatibility complex class I molecules (MHC-I), which is 
responsible for antigen presentation to CD8 T cells [43, 44]. MHC molecules are also 
inhibited by the virion host shutoff protein (VHS) [45, 46], a tegument protein that along 
with immune inhibition [47, 48], is also responsible for the degradation of both host and 
viral mRNAs, ensuring efficient and effective viral replication [49].  
The E genes then act as the IE genes before, being translated into E proteins that 
enter the nucleus. The key E genes will activate the L (γ) genes and lead to HSV-1 
genome replication [50]. Early genes UL5, UL52, and UL8 form a heterotrimeric complex 
that will perform DNA primase activities leading to the replication of the HSV-1 genome 
[51] along with the DNA polymerase enzyme UL30 [20, 52]. Lastly, the L genes will be 
translated in identical fashion, and the L proteins will lead to capsid formation and genome 
assembly [53]. The now assembled and completely replicated HSV-1 genome is prepared 
to exit the host cell.  
1.3.3. Viral Egress 
The first step in virion egress is the formation and insertion of the genome into a 
fully formed viral capsid. The viral capsid is constructed with L proteins VP5 (UL19) which 
is known as the major capsid protein, VP21 (UL26) and VP22a (UL26.5) which form the 





icosahedral shell that defines the viral capsid [54-56]. The viral DNA is then packaged via 
viral proteins UL6 [57], UL15 [58], UL17 [59], UL28 [60], UL32 [61], and UL33 [62, 63]. 
The viral capsid containing viral DNA will then leave the nucleus and enter the cytoplasm. 
To exit the nucleus, the viral capsid – now too large to exit via a nuclear pore - 
must fuse with the inner nuclear membrane (INM) of the host cell. This fusion, or primary 
envelopment, occurs through a UL31 and UL34 protein complex that allows the viral 
capsid to enter the perinuclear space between the INM and the outer nuclear membrane 
(ONM) by modifying the INM structure [64-66]. The capsid, through interactions with gB, 
gH, and gL will fuse with the ONM, releasing the viral capsid into the cytoplasm through 
a process called de-envelopment [67, 68]. Once inside the host cell cytoplasm, tegument 
proteins will bind to the capsid, creating the viral tegument that will undergo secondary 
envelopment, as the tegument will be covered in the viral envelope as it moves through 
the trans-golgi network (TGN) and exits the TGN located within a membrane vesicle [69-
71] . The vesicle will migrate to the plasma membrane where it will finally be exocytosed 
through the aid of gK [72] to extracellular space or to adjacent cells via cell-cell junctions 
binding through gE and gL [73].  
2. Herpes Simplex Virus 1 Latency 
2.1. HSV-1 Latency Overview 
Latency, or the ability of a virus to exist in a non-active non-replicative state is a 
key survival mechanism utilized by HSV-1.  Latency can only occur within the nucleus of 
a neuron [74], and during the course of lytic infection, the virus gains access to the 
nucleus of neurons located in the TG through the process of retrograde transport (Figure 





the dendritic terminals of neurons, thus only the tegument and viral capsid, much like in 
the lytic replication cycle, will enter into the dendrite [75]. Dynein, a motor protein that 
moves material from the positive to the negative direction (retrograde) along cell 
microtubules, will then bind to the HSV-1 capsid via interactions with viral proteins pUL37 
and VP1/2 (among others), and transport the virus to the nucleus of a now infected neuron 
[17, 34, 75-77]. Once the virus reaches the neuronal soma, the viral DNA will be inserted 
in the nucleus as previously described (Section 1.3.1). 
After gaining access to the nucleus of a neuron, the virus will undergo some 
replication, leading to subsequent infection of surrounding cells which includes other 
neurons, satellite glial cells (SGCs), and Schwann cells that make up the TG [78, 79]. The 
actively replicating virus in the TG will spread to surrounding cells via cell-to-cell 
interactions where transport is mediated by viral proteins gE and gL [73], and recent 
evidence indicates that there is fusion between neurons and SGCs that facilitates viral 
spread [80]. The hallmark of the herpes virus however, is its ability to enter a non-
replicative latent state in neuronal cells once it reaches the cell nucleus. 
As the virus enters its latent state, no viral proteins or mRNA will be present; rather, 
the only detectable gene product of HSV-1 during latency is the latency associated 
transcript (LAT) [81, 82]. LAT is a 2.0 kb intron, non-coding RNA, encoded near the 3’ 
region of the IE protein ICP0 [81, 83, 84]. The LAT intron has been found present in a 
precise subset of neurons that are specific for the A5 antibody, while productive infection 
is localized to KH10+ neurons [85-88]. Further, LAT helps to prevent the apoptosis of 
infected neurons, therefore, infected neurons will not die like other cells in which only lytic 





latent virus residing in the TG, though it should be noted that the presence of LAT may 
not correlate to the amount of viral DNA present in the neuron of a latently infected TG, 
and therefore while LAT is an effective marker to measure HSV-1 latency, it does not 
represent the viral load in the TG [90, 91].  Current research is still unable to identify how 
this latency is established, maintained, and what causes reactivation.  
When reactivation occurs, however, the LAT transcript will no longer be expressed 
and the viral replication cycle will be initiated starting with ICP0 [38]. The viral replication 
cycle will then proceed, leading to both cell-to-cell spread within the TG, and transport of 
the virus to mucosal surfaces [80, 92]. To spread from neurons to the mucosal surface, 
the virus will undergo anterograde transport (transport from the negative to positive end 
of a microtubule) along the axon via the motor protein kinesin [17, 77]. Kinesin will 
transport the virus as either a fully enveloped capsid (married-model) or as a capsid and 
envelope separately (separate-model) [93, 94]. Which model is used is still widely 
debated as evidence has been found to support both models, but each supports the idea 
that viral proteins gE, gL, and pUS9 are heavily involved in the transport of the virus to 
the dendritic end terminals of the axon where the virus will then exit fully enveloped [93-
95].  
2.2. The Role of the Immune System in the Establishment of HSV-1 Latency 
As stated, little is still known about the exact mechanism by which HSV-1 is able 
to establish life-long latency in the neurons of the TG, but evidence does indicate that the 
immune system plays a substantial role [96]. After primary infection of the mucosal 
epithelium, the virus will travel to the TG where the immune response will function to aid 





the innate immune response will be triggered by pathogen associated molecular patterns 
(PAMPs) recognized by host toll-like receptors (TLR) 2,3, and 9 [16, 98-101] and a large 
influx of polymorphonuclear leukocytes (PMNs) will occur at the site of infection [96, 102]. 
The TLRs then activate downstream events via NF-κB signaling, leading to the production 
of type 1 interferons (IFNs) such as IFNγ and IFNα [103, 104]. Along with this influx of 
chemokines, there will also be an increase in PMNs, which serve to activate dendritic 
cells (DCs), the key antigen presenting cell (APC) leading to both CD8 and CD4 T cell 
activation in the draining lymph node [103-106]. This T cell activation is a key component 
in the establishment of latency due to the importance of CD8 T cells to the immune 
response in the TG, which differs from the immune response seen at the mucosal surface 
[102]. 
In the TG, CD8 T cells act as the key immune cell responsible for the establishment 
of HSV-1 latency. Early studies indicate that depletion of CD8 T cells prevents viral 
latency and leads to a decrease in viral clearance from the TG [97, 107, 108]. Concurrent 
with these findings, the immune response in the TG is heavily reliant on the CD8 T cell 
influx with a smaller CD4 T cell response and almost no PMN infiltration [102, 106]. This 
CD8 T cell influx is bolstered by IFNα, as treatment of neurons with IFNα has been shown 
to increase the number of LAT positive neurons indicating an ability to increase viral 
latency through the prevention of lytic replication [109, 110]. 
Evidence also points to the role of other immune cell types in the establishment of 
latency. CD4 T cells are responsible for improving the CD8 T cell response to HSV-1 [97], 
which is accomplished via increased IFNγ and TNFα; where the production of both 





activation and programming of HSV-1 specific CD8 T cells [112]. DCs may also play a 
prominent role in the establishment of latency; specifically, CD8α DCs, which are involved 
in the production of type 1 IFNs [113]. These CD8α DCs appear to drive the expression 
of LAT, even in the absence of CD8 T cells [114, 115]; and CD8α DC depletion via 
granulocyte-macrophage colony-stimulating factor (GM-CSF), which drives down the 
development of CD8α DCs, decreased LAT transcription in the TGs of these mice [116]. 
The authors of this work indicated that less total LAT in an individual cell may be an 
indicator of a decreased potential for recurrent infection [91, 117].  
2.3. The role of the immune system in the maintenance of HSV-1 latency 
HSV-1 latency is marked by a lack of viral replication both at the mucosal surface 
and in the TG, combined with the presence of LAT in neuronal nuclei of the TG [74]. While 
the initiation of latency provides a survival mechanism for the virus from the immune 
system, the immune response is also responsible for maintaining LAT expression and 
preventing activation of IE genes [97, 118, 119]. Studies of autopsied human subjects 
indicate a strong presence of CD8 T cells, IFNγ, and TNFα in TGs that contain LAT [118, 
119]. Thus, the role of CD8 T cells does not end at the establishment of latency, but rather 
continues throughout the life of an infected individual. 
CD8 T cells act as a patrolling immune cell in the TG, maintaining viral latency 
through recognition of the late HSV-1 protein, gB; specifically the gB498-505 epitope [120]. 
While it is reported that only 50% of circulating CD8 T cells in the TG recognize HSV-1 
epitopes, the ability of CD8 T cells in the TG to recognize the gB epitope allows for the 
inhibition of viral reactivation [121, 122]. These gB specific T cells also appear to be a 





[123]. The importance of resident TG CD8 T cells is demonstrated through experimental 
studies wherein cultures of infected TGs supplemented with exogenous CD8 exhibit 
delayed HSV-1 reactivation, and similar cultures treated with anti-CD8 display enhanced 
viral reactivation [124]. CD8 T cells are also depleted by physiological stress (often 
associated with a lowered immune response) leading to increased viral reactivation [125].  
Further, the patrolling CD8 T cells in the TG are also found to be actively secreting 
IFNγ, which is able to suppress viral reactivation in infected TG cultures [122, 126, 127]. 
Just as importantly, inhibition of IFNγ decreases the ability of CD8 T cells to maintain 
HSV-1 latency [126, 127], as evidenced by the decrease in both CD8 T cells and IFNγ in 
stressed mouse models [125]. The secretion of IFNγ by the CD8 T cells is a key 
component in an autocrine feedback loop in which IFNγ increases the expression of 
programmed cell death ligand (PD-L1) which increases apoptosis of CD8 T cells, and 
inhibits the expression of the IE protein ICP0 [127, 128]. However, as indicated, less IFNγ, 
and consequently PD-L1, will lead to an increase in CD8 T cell numbers; but these T cells 
will express low levels of granzyme B, a serine protease involved in the cleavage of IE 
protein ICP4 [129]. Thus, a CD8 T cell increase mediated through a decrease in IFNγ is 
not functionally able to maintain HSV-1 latency [128]. 
While the immune response to HSV-1 is effective in maintaining latency, LAT is 
also involved in inhibiting various immune functions to allow it to survive as well [130, 
131]. As mentioned, there is an increase in PD-L1 during latent infection, indicating T cell 
exhaustion and ultimately apoptosis [128]. This induction of exhaustion is mediated 
through increased levels of both MHC-I and PD-L1 in LAT+ mice in comparison to LAT- 





exhaustion of CD8 T cells leading to eventual reactivation [132]. In concurrence with this 
exhaustive role, the presence of LAT is found to increase HSV-1 antigen specific DCs, 
leading to an exhaustive level of CD8 T cell activation [133]. Further, LAT has been shown 
to prevent apoptosis of the neuronal cells in which they reside [89, 130, 134], which 
protects from the granzyme B induced apoptosis induced by the resident CD8 T cells 
[135].  
2.4. Herpes Simplex Virus Encephalitis 
While corneal induced blindness is a very severe and challenging outcome to HSV-
1 infection and reactivation, the most devastating outcome of HSV-1 infection is herpes 
simplex virus encephalitis (HSE), where HSV-1 accounts for 90% of all HSE [136]. HSE 
occurs when the virus is transported not to the epithelial surface, but to the central 
nervous system (CNS), where the immune system is ill-equipped to prevent the spread 
of the virus and death of neurons [137]. The mortality of such infection can be as high as 
70% if not treated early, and the cause of infection in adults is most often associated with 
viral reactivation from a latent state [138, 139]. Presenting as a neurological disease, 
symptoms of HSE include fever, headache, nausea, and behavioral changes, among 
other symptoms [136]. Currently, the best way to detect HSE is through culture of HSV 
from the brain, identification of a high HSV anti-body titer in cerebral spinal fluid (CSF), or 
HSV DNA detection in the CSF via PCR [136, 139, 140].  
As reactivation is the most common cause of HSE [139-141], much of the study 
on viral reactivation can be extrapolated to include the potential for HSE. However, there 
are some studies that have found that there are some specific immune mechanisms 





as TLR3 is found to improve the ability to combat HSV-1 infection of the CNS [142, 143]. 
Studies in the mouse model have indicated that TLR2, a key inflammatory protein 
involved in the initiation of the immune response, actually may be associated with HSE, 
as TLR2 deficient mice showed decrease inflammation of the CNS associated with CSE 
[98]. In contrast, a study focused on TLR2 and TLR9 demonstrated that reduced 
activation lead to an increase in viral spread to the CNS [137]. Current treatment for HSE 
is an early administration of acyclovir that reduces viral levels in the CNS and decreases 
HSE mortality [139, 144]. 
3. Neurotrophic factors and Neuropeptides 
The TG consists of neuronal cell bodies which communicate via neuropeptides, 
neurotransmitters, and neurotrophic factors [145]. Neuropeptides can thus act to 
modulate and alter other neurons and cell types via neuropeptide receptors [145]. While 
there are many neuropeptides produced throughout the central and peripheral nervous 
systems, the TG has a fairly large profile when it comes to neuropeptide expression [146, 
147]. The most commonly expressed neuropeptides in the TG are: tachykinins, calcitonin 
gene-related peptide (CGRP), somatostatin (SST), vasoactive intestinal peptide (VIP), 
galanin, and neuropeptide Y (NPY) [147, 148]. The heavy presence of neuropeptides is 
especially important in its ability to modulate immune cells, a key component to HSV-1 
latency [149]. 
3.1. Calcitonin Gene Related Peptide 
CGRP is a neuropeptide that consists of 37 amino acids and is found fairly highly 
expressed within neurons of the TG [146, 147]. Highly implicated in migraine and pain 





CGRP has been shown to both increase and decrease the immune response. As an 
inhibitor, CGRP inhibits the production of IL-2 and thus Th1 CD4 T cell proliferation [151, 
152]. This inhibition leads to a decrease in IFNγ, and an increase in several TH2 type 
cytokines [153]. Similarly, TNFα and IL-12 are inhibited by the upregulation of IL-10 by 
CGRP, possibly demonstrating an inhibition in antigen presentation by GM-CSF [154, 
155]. Indicative of the dual roles that CGRP may play, the peptide has been shown to 
increase various immune mechanisms, such as increasing T cell adhesion via fibronectin 
and adhesion to vascular endothelial cells [156, 157]. Further, CGRP has been 
demonstrated to increase immature DC migration [158] and T cell migration [159]. 
Due to its abundant expression within the TG, CGRP has been studied in the HSV-
1 infection model. CGRP immunoreactivity level has been shown to be decreased in 
mouse neurons infected with the LAT transcript [160], however in a study of human TGs, 
CGRP is expressed more often with LAT positive cells [88]. Also, HSV-1 does not appear 
to infect CGRP positive neurons within the TG at an increased rate [161]. CGRP 
increases IL-1β in macrophages under HSV-1 infection, but less so in macrophages of 
uninfected mice [162]. Ultimately, the role of CGRP during HSV-1 infection is not entirely 
clear. 
3.2. Somatostatin 
Somatostatin, consisting of functionally similar 14 and 28 amino acid isoforms, 
while not as highly expressed in the TG as SP and CGRP, plays a pivotal role in immune 
function [163]. Somatostatin has five different receptors (SSTRs 1-5) that have been 
identified on various immune cells [164]. Interestingly, consensus has not been reached 





T cells, while mouse studies show SSTRs 1, 2, and 4 on various mouse T cells, and 
SSTR3 on human T cells [164-166]. Perhaps most interestingly, there is lack of 
consensus on the effect somatostatin has on T cells [163]. For example, in human Jurkat 
T cells, somatostatin increased IL-2 production [165], as well as IL-4 and IL-10 [167], and 
somatostatin increased T cell adhesion [156]. However, somatostatin inhibits IFNγ 
production (in opposition to substance P) [168, 169], T cell proliferation [170], and 
increases T cell apoptosis in peripheral blood lymphocytes [171, 172]. Currently, there 
are no studies indicating that research has been done on the potential effects of 
somatostatin during HSV-1 infection. 
3.3. Vasoactive Intestinal Peptide 
Vasoactive intestinal peptide (VIP), expressed moderately by TG neurons, has 
been identified as an important anti-inflammatory, immunomodulatory, neuropeptide 
[147, 148, 173]. Receptors for VIP, primarily VPAC1 and VPAC2, are found expressed 
on a variety of immune cells [173]. VIP’s effects have been mostly studied on 
macrophages, as VIP has been found to greatly inhibit the cytokine production and 
antigen presentation of macrophages [174, 175]. In relation to the immune response seen 
in HSV-1, VIP has been found to decrease IL-2 [176, 177], IL-4 [178], IL-12 [179], and 
IFNγ [179] leading to an inhibition of Th1 CD4 T cells, leading a shift towards Th2 CD4 T 
cells [178, 180] via increased IL-10 [181] and IL-6 [182]. In a pro-inflammatory role, VIP 
was found to induce DC maturation via an increase in TNFα [183]. That being said, it is 
important to note that there are contradictory studies that indicate a different effect by VIP 





6 [187], and TNFα [188]. Thus, any future studies into VIP should take these reports into 
account as well.  
3.4. Neuropeptide Y and Galanin 
Of the remaining neuropeptides in the TG, NPY and galanin are the least 
expressed [147]. However, NPY receptor Y1 has been identified on every immune cell 
type in both mice and humans [189]. Like VIP, NPY shows the ability to increase IL-4 
while decreasing IFNγ, indicating a role in TH2 CD4 T cell production [167, 190]. Primarily 
acting via sympathetic nerves, NPY plays a role in T cell recruitment and adhesion [156, 
159, 167], but NPY was found to decrease lymphocyte proliferation via inhibition of IL-2 
at an increasing rate with age [191, 192]. The effect of NPY has been demonstrated on T 
cell priming via decreased APC activation [193], and it was shown to decrease IL-6 
expression by macrophages [194].  
The other peptide, galanin, mostly involved in pain and injury response [195-197], 
appears to have a lesser effect on the immune response. Galanin has been shown to be 
active mostly on the innate immune response as peptide expression leads to reduced 
TNFα [198], increased IL-1α and IL-8 in the skin [199], and increased PMNs via increases 
in cytokine production [200]. There is also some evidence that galanin may play a role in 
increasing apoptosis and decreasing thymocyte proliferation via its receptors GalR1 and 
GalR2 [201]. Interestingly, galanin expression has been shown to be modulated by HSV, 
as infection leads to an increase in galanin expression in TG neurons starting around day 
6 post-infection, continuing up to day 14 post-infection, where it proceeds to normal levels 
by day 21 post-infection [202, 203]. However, it is unclear the effect this expression 





3.5. Substance P 
Expressed close to the same level as CGRP within the TG, substance P (SP) is 
found co-localized with CGRP in TG neurons almost 100% of the time [204-206]. SP is 
part of a larger group of peptides known as tachykinins [207]. Like CGRP, SP is found to 
modulate the immune system. In direct opposition to CGRP, SP was found to decrease 
T cell adhesion via binding with the SP receptor neurokinin 1 receptor (NK1R) [156]. 
However, SP appears to be overall pro-inflammatory as evidenced by the peptide’s ability 
to increase the proliferation of T cells [208, 209]. More specifically, SP can increase the 
IL-2 production of T cells [210] as well as IFNγ [211, 212], which appears to generate an 
increase in CD4 T cells [209]; although other reports indicate that SP enhances the 
production of TH17 T cells [212]. 
Again, like CGRP, the involvement of SP in the immune response and significant 
presence within the TG made it a candidate for study in HSV-1 infections. Along with 
CGRP, it stimulates the production of IL-1β in macrophages of HSV-1 infected mice [162, 
213]. In the case of corneal infection, SP has been found to increase the detrimental 
immune response during ocular HSV-1 infection via increased production of IFNγ and 
other pro-inflammatory molecules [214]. In respect to the TG during HSV-1 infection, SP 
was shown to increase in the TG of mice given chemical sympathectomy treatment [215], 
while research on LAT within the TG has demonstrated that LAT increases the expression 
of SP in cultured TG neurons [216]. 
3.6. Neurokinin Receptors 
As stated, SP is a member of a larger family of peptides known as tachykinins 





Neurokinin B (NKB), and Hemokinin-1 [218].  The tachykinin peptide family binds to three 
different receptors, all at different affinities; those receptors are neurokinin receptors 1, 2, 
and 3 (NK1R, NK2R, and NK3R) [217]. Each receptor is a g-protein coupled receptor that 
is around 400 amino acids in size [217, 219]. The most commonly expressed and studied 
receptor is NK1R, which has the highest affinity for SP, followed by NKA, then neurokinin 
B NKB [217, 219]. These affinities change for NK2R (NKA > NKB > SP) and NK3R (NKB 
> NKA > SP) [218, 219].  
The expression and impact of neurokinin receptor signaling is very broad and 
opens opportunities for study in a variety of fields. As mentioned, NK1R is the most 
ubiquitously expressed neurokinin receptor, as it has been identified in neurons, vascular 
endothelial cells, immune cells, and many others [218]. This expression on immune cells 
is further demonstrated through studies that have shown that NK1R is upregulated during 
inflammatory conditions, and provides further evidence to the pro-inflammatory role of SP 
[219]. The expression of NK2R and NK3R is much more limited however, as NK2R is 
mostly detected in the nervous system, and NK3R has been identified as a primarily a 
central nervous system expressed receptor with expression in a few peripheral nervous 
tissue locations [218]. Similar to NK1R however, both NK2R and NK3R are found to be 
affected by inflammatory cytokines, although research on the receptors has been limited 
compared to NK1R [219]. Overall, the expression of all three neurokinin receptors in the 
peripheral nervous system, in conjunction with the response by all receptors and SP to 







4. Localized Cell Response in the TG 
4.1. Anatomy of the TG 
The trigeminal ganglion (TG), also known as the fifth cranial nerve, consists mostly 
of afferent or sensory nerve fibers [78]. These nerve fibers are part of the peripheral 
nervous system (PNS) so there are both myelinated and unmyelinated nerve fibers 
present in the tissue [78]. The TG consists of three cell types: (1) pseudounipolar neuronal 
cell bodies that receive information from the facial and ocular surface that is sent in a 
retrograde fashion to the brainstem [220]; (2) satellite glial cells (SGCs) that surround 
these neuronal cell bodies and provide structural and functional support [221]; and (3) 
Schwann cells, a specialized glial cell responsible for the myelination and bundling of 
nerve fibers [147]. This morphology is further characterized by three separate branches 
of the TG that enter the orofacial region [78, 79]. The three branches are: the ophthalmic 
branch (V1) that extends to the ocular surface, the maxillary branch (V2) that extends to 
the upper lip area, and the mandibular branch (V3) which extends to the lower lip and 
jaw, and is the only branch of the TG to contain a small number of efferent (motor) 
neurons (Figure 4) [78]. 
4.2. Response to pain and inflammation 
As demonstrated, the immune response within the TG is a key factor in both 
establishing and maintaining HSV-1 latency, and neuropeptides produced by TG 
neurons, with their ability to modulate the immune response can have an effect on latency 
as well. However, evidence indicates that the key support cell, SGCs, may play a pivotal 
role in latency as well [222-224]. In the TG, the SGCs are found surrounding the neuronal 





interaction allows the SGCs to perform their primary function, the recycling of glutamate 
[221, 226]. During neuronal signaling, neurons will produce glutamate as a by-product, 
which if allowed to build up, can lead to neuronal death and decreased cell signaling 
[226]. SGCs thus act through the enzyme glutamine synthetase (GS) to convert toxic 
glutamate to glutamine, which is used by neurons to continue synaptic transmission 
(Figure 5B) [226, 227]. The close interaction with neurons is also utilized by the SGCs to 
communicate with surrounding neurons and glial cells via extensive gap junctions that 
increase following injury or inflammation [79, 227, 228]. 
These close interactions indicate a potential impact on HSV-1 latency created 
through neuropeptide signaling and various neurotrophic factor signaling on these cells 
as well. Primarily, neurotrophic factors nerve growth factor (NGF), glial cell line-derived 
neurotrophic factor (GDNF), neurotrophin-3 (NT-3), and ciliary neurotrophic factor (CNTF) 
are implicated as having a potential effect on SGCs and neurons during injury and 
inflammation [229-231]. These neurotrophic factors play a role in cell survival, as one 
study found that GDNF will promote neuron survival in culture, while BDNF and NGF 
promoted CGRP release, increasing neuronal sensitivity [232, 233]. Further, NGF was 
found to increase SP expression in neurons, indicating a potential impact on the effects 
SP may have during HSV-1 infection [234]. In response to inflammation in arthritis, SGCs 
were found to increase in proliferation [235], and there are also a variety of reports that 
indicate that SGCs may both express and have receptors for a variety of the 
aforementioned neurotrophic factors, though the role of this effect is yet to be fully 





As previously described, neuropeptides in the TG have a great effect on immune 
cell function. However, neurons and SGCs can further this immune function, perhaps 
increasing the neuropathic pain response [236]. SGCs, for example, have been 
demonstrated to increase cytokines via monocyte chemotactic factor  protein-1 (MCP-1) 
and increase cytokines TNFα [237], IL-1β [238], and IL-6 [239] in response to injury. 
SGCs have also demonstrated the expression of a variety of immune cell associated 
markers such as CD45, CD11b, and CD11c among others [240]. Interestingly, it has been 
demonstrated that pain response is facilitated by the Th1 CD4 T cells and inhibited by the 
Th2 CD4 T cells; thus, the potential ability of HSV-1 infection to induce pain may affect 
the immune response to infection without responding directly to the infectious virus [241]. 
In fact, both macrophages and T cells were found to increase in the dorsal root ganglia 
(DRG) in response to injury alone, where macrophages further will access the neuronal 
soma by migrating via SGCs [242, 243].  
Overall, the effects of these neurotrophic factors and neuropeptides in the TG on 
SGCs manifest themselves most often via the immune response, perhaps even 
contributing to neuropathic pain. CGRP, for example, has been found to act on SGCs 
leading to inflammatory cell increase by these SGCs and SGCs were found to act in an 
autocrine loop to increase CGRP expression in neurons. Such inflammatory cells include 
key HSV-1 infection molecules IL-6, IL-10, and TNFα [79, 238, 244]. Neurons will also 
increase CGRP and SP in response to inflammation, further affecting the immune 
response of these neuropeptides [245, 246].  Therefore, there is substantial evidence 
indicating that the local cell response during HSV-1 infection in the TG may play a 













Figure 2: Herpesvirus Lytic Replication Cycle.The virion enters the cell by attaching to host 
cell glycoproteins (1) and fusing with the host cell membrane (2). This allows for the entry of 
the viral capsid (3) which localizes to the host nucleus (4) and the viral genome is inserted 
into the host cell (5). The virus then utilizes the host cell machinery to transcribe viral genes 
and translate viral proteins (6-11). Replicated virus then assembles the genome into a newly 
formed nuclear capsid and exists the nucleus (12). The new capsid is engulfed through the 
trans-golgi network and the viral envelope is formed (13). Finally, fully enveloped virion is 






Figure 3: Viral Latency Establishment. The viral particles gain access to 
pseudo-unipolar neurons of the TG through fusion of the viral envelope with 
neuronal varicosities (1). The viral capsid will move along the axon via dynein 
and enter the nucleus (2), shedding its viral capsid and expressing only the 






Figure 4: The human TG.The human trigeminal ganglion is located near the 
brain stem and has three branches: The ophthalmic (V1), the mandibular (V2), 
and the maxillary (V3). Image modified from a work by Thom Graves and the 






Figure 5: Satellite glial cells surround neurons providing structural and functional support. (A) 
Artist depiction of a neuron surrounded by satellite glial cells in the peripheral nervous system. 
(B) Depiction of the recycling of glutamate by the enzyme glutamine synthetase present in the 





MATERIALS AND METHODS 
Mice 
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). 
Breeding pairs of NK1R-/- mice were originally provided by Dr. Norma P. Gerard (Boston’s 
Children Hospital, MA), and the mice were then bred at the Wayne State University 
School of Medicine Division of Animal Laboratory Animal Resources (DLAR). To confirm 
genotype of the NK1R-/- mouse line, tail biopsy was performed using polymerase chain 
reaction and subsequent gel electrophoresis (Figure 6). For experimental procedures, 
eight to twelve-week-old female mice were used. All mice were housed at the Wayne 
State University DLAR in accordance with the Association for the Accreditation of 
Laboratory Animal Care approved guidelines. All experimental procedures were carried 
out in accordance with the Institutional Animal Care and Use Committee (IACUC) and the 
Association for Research in Vision and Ophthalmology. 
Ocular HSV-1 infection 
To carry out ocular HSV-1 infection, mice were anesthetized via intraperitoneal 
injection of a ketamine (33 mg/kg body weight) and xylazine (20 mg/kg body weight) in 
0.2 ml of PBS. Virus used was propagated on a monolayer of VERO cells and infected 
cells suspended in PBS underwent three rapid freeze-thaw cycles in liquid nitrogen and 
a 37°C water bath, respectively. The cell suspension was then centrifuged, and infectious 
virus found in the supernatant was titrated on VERO cells prior to storage in aliquots at -
80°C. Mouse corneas were then scarified using a 27 ½ gauge needle and HSV-1 was 
topically applied to the scarified eyes in 3 μl of PBS followed by gentle massage of the 





RNA isolation, cDNA synthesis, and Real-Time quantitative polymerase chain 
reaction (RT-qPCR) 
TG tissues for qPCR were collected (Figure 7) in a solution of RNA-STAT60 (Tel-
Test, Inc, TX, USA) and homogenized using a Qiagen Tissue Lyser (Qiagen, MD, USA). 
For corneal samples, enucleated eyes were dissected under a stereomicroscope in a 
solution of RNA Later (ThermoFisher Scientific, MA, USA) before being placed in RNA-
STAT60. RNA was extracted from the homogenized solution using a chloroform solution. 
RNA was then precipitated with isopropanol, washed with ethanol, and air-dried. To 
ensure a more pure RNA solution, the RNA solution underwent DNase treatment using a 
DNA-free Kit (ThermoFischer Scientific, MA, USA, #AM1906). Purified RNA was 
converted to cDNA using an iScript cDNA Synthesis Kit (Bio-Rad, CA, USA) and run on 
a CFX Connect Real-Time System (Bio-Rad, CA, USA) using SSOAdvanced Universal 
SYBR Green Supermix (Bio-Rad, CA, USA). A list of BioRad PrimePCR primer assay IDs 
used can be found in Table 1. Quantification of the relative mRNA expression (ratio) of 
the primers in tissue was calculated using the ΔΔCq method [248] for the gene of interest 
(GOI) with GAPDH as the sample control as follows: Ratio = 2
Cq GOI Naive −Cq GOI Infected
Cq GAPDH Naive−Cq GAPDH Infected.  
For copy number quantification, viral mRNA and cDNA was generated as 
mentioned. The standard curve for which to measure known copy numbers was 
generated from viral plasmids for either gB or LAT (gifted by Dr. Homayon Ghiasi, Cedars-
Sinai Burns and Allen Research Institute, CA). The plasmid standard curve was run 
simultaneously with sample cDNA using FAM labeled TaqMan gene expression assays 
(Applied Biosystems, MA, USA) and TaqMan Universal PCR Mastermix (Applied 





copy number quantification of viral DNA, samples were dissected, and DNA was isolated 
using a DNeasy Blood and Tissue Kit (Qiagen, MD, USA). DNA samples were run with 
plasmids as mentioned. All primers used identified in Table 2.  
Tissue Processing  
Single-cell suspensions were generated from TGs, lymph nodes, and spleens. TG 
single cell suspensions were generated as excised TGs were placed in a DMEM 
collagenase type IA solution (3 mg/mL, Sigma-Aldrich, MO, USA) in a Disruptor Genie 
(Scientific Industries, NY, USA) at 37°C for 30 minutes. After 30 minutes, TGs were further 
triturated with a 200 μL pipette tip prior to centrifugation followed by pipetting to a single 
cell suspension for flow cytometry or myelin removal.  Cornea samples were placed in a 
solution of RPMI and Liberase TL (2.5mg/ml) after the eyes were enucleated and corneas 
were cleanly dissected under a stereomicroscope. Corneas in the RPMI Liberase solution 
were placed in a Disruptor Genie at 37°C for 45 minutes and triturated using a 3 ml syringe 
plunger. Samples were passed through a 70 μm cell strainer, pelleted down via 
centrifugation, and broken into a single-cell suspension. Lymph nodes and spleens were 
homogenized with a 3 ml syringe plunger in a solution of RPMI, filtered through a 70 μm 
cell strainer, pelleted down via centrifugation, and broken into a single-cell suspension. 
Spleen samples were processed as lymph nodes, and treated with red blood cell lysis 
buffer prior to generating a single cell suspension. 
Flow cytometry cell surface staining 
Cell surface staining was carried out by placing single-cell suspensions in a 96 well 
u-bottom plate. Cells were washed with FACS buffer, followed by the blocking of FC 





antibodies used as identified in Table 3. Primary antibodies NK1R (N-19 clone, Santa 
Cruz Biotech, CA, USA ), and NK3R (NB300-201, Novus Biologicals, CO, USA) were 
added at a dilution of 1:00, followed by secondary antibody of Alexa 647 (Life 
Technologies, MA, USA) at 1:200 (Table 3). All samples were acquired on a BD LSR II 
flow cytometer (BD Biosciences, CA, USA). All data analyzed using FlowJo Software 
(Ashland, OR). 
Intracellular cytokine staining and ex-vivo stimulation 
For the staining of intracellular cytokines, cell membranes were permeabilized with 
Cytofix/Cytoperm (BD Biosciences, CA, USA) as per manufacturer instructions, and 
antibodies were added. To stimulate the production of intracellular cytokines, lymph 
nodes from infected mice were processed into single cell suspensions as mentioned 
previously. Single cell suspensions were then incubated at 37°C, 5% CO2 in a solution of 
RPMI media containing fetal bovine serum (FBS) (GE Healthcare, UT, USA), IL-2 (R&D, 
MN, USA) , and 10 µg/mL SSIEFARL (gB) peptide (GenScript, NJ, USA). After two hours, 
Brefeldin A (Sigma, MO, USA) was added at a concentration of 10 µg/mL and incubation 
continued for four more hours. After incubation, cell surface staining and intracellular 
cytokine staining were carried out. Intracellular cytokine staining for conjugated 
antibodies: anti-IFNγ conjugated to PE and anti-TNFα conjugated to PE-Cy7 (Table 3). 
Primary antibody to glutamine synthetase (Ab178422, Abcam, MA, USA) was used at a 
concentration of 1:100 followed by secondary antibody of Alexa 647 at a concentration of 







Flow cytometry Ki-67 staining 
For nuclear Ki-67 staining, isolated lymphocytes or TG cells were permeabilized 
with a fixation/permeabilization buffer (ThermoFisher, MA, USA), and cells were stained 
using a PE mouse anti-human Ki-67 antibody (BD Pharmingen, CA, USA). Surface stains 
and intracellular staining as previously mentioned. 
Ex-vivo viral reactivation assay & SGC culture 
Ex-vivo reactivation was used to measure latent reactivation rates. In this system, 
latently infected TGs at day 18 post-infection were excised and individually placed into a 
well of a 24 well poly-D-lysine coated plate (Sigma-Aldrich, MO, USA) containing DMEM 
supplemented with 10% FBS and 50 U IL-2 (R&D, MN, USA) and kept in an incubator at 
37°C, 5% CO2. Daily, 200 µL of media was removed from the well containing the TG and 
placed on a monolayer of VERO cells in a 24 well plate. This process was repeated daily 
for 10 days. VERO cells were then monitored daily for signs of viral reactivation, identified 
through phenotypic changes marked by the presence of rounded cells that detached from 
the plate surface (Figure 23). The earliest day of reactivation was recorded. 
Confocal microscopy and corneal whole mount staining 
 Tissues for imaging were excised and immediately placed in OCT solution 
(Tissue-Tek, CA, USA). TGs were placed lengthwise in OCT solution and eyes were 
enucleated and placed in OCT solution. OCT with tissue was snap frozen in liquid nitrogen 
and stored at -80°C. Blocks were sectioned at 8 μm sections for corneas and 10 μm 
sections for TGs and placed onto glass slides. Samples were then fixed in 2% 
paraformaldehyde, followed by blocking with a 3% BSA 1% TritonX-100 solution. 





The next day, samples were washed with a 0.3% Triton X-100 PBS solution and a 
secondary antibody was added for 2 hours at room temperature in a humidified chamber. 
Samples were then mounted with a Vectashield medium containing DAPI (Vector 
Laboratories, CA, USA) prior to acquisition on a Leica TCS SP8 confocal microscope. 
Corneal whole mount staining was conducted on enucleated eyes, wherein 
eyeballs were fixed immediately in 4% paraformaldehyde for 30 minutes at room 
temperature. Corneas were then dissected using a scalpel blade and corneal scissors 
under a dissecting microscope. Corneas were flattened by making six to eight cuts from 
the central cornea to limbal area and placed in 30% sucrose overnight at 4°C. Next, 
corneas were permeabilized with a solution of 0.1% EDTA and 0.01% hyaluronidase type 
IV-S solution and kept at 37°C for 90 minutes. Samples then underwent blocking in 3% 
BSA 1% TritonX-100 at room temperature for 90 minutes. Tissues were then incubated 
in a humidified chamber for 16 hours at 4°C in a dilution of primary antibody in 1% BSA-
0.3% TritonX-100. The next day, tissues were washed with 0.3% TritonX-PBS solution, 
followed by secondary antibody (if necessary) in a solution of 1% BSA-0.3% TritonX-100 
overnight in a humidified chamber at 4°C. Samples were mounted with Vectashield 
mounting media containing DAPI (H1200; Vector Laboratories, CA, USA) before 
acquisition on a Leica TCS SP8 confocal microscope. 
Antigen presentation Assay with DC2.4 cells 
Spleens from OT-II mice (B6.Cg-Tg (TcraTcrb) 425Cbn/J, Jackson Labs, ME, 
USA) were, processed for flow cytometry as previously described. After red blood cell 
lysis, CD4+ T cells were isolated using CD4+ T Cell Isolation kit instructions (Miltenyi 





ThermoFisher, MA, USA). DC2.4 dendritic cell line cells (Millipore-Sigma, MO, USA) were 
irradiated at 3,000 rad and pulsed with ovalbumin323-339 for 30 minutes at 37°C, 5% CO2. 
Pulsed DC2.4 cells were then co-cultured with CD4 T cells at a 1:10 DC:T Cell ratio (2x104 
DCs:2x105 T cells) for 3 days in a 96 well U-bottom plate at 37°C, 5% CO2. After 
stimulation, cells were acquired via flow cytometry as previously described. 
Antigen presentation assay using satellite glial cells 
Ovalbumin specific T cells were acquired and labeled with CFSE as previously 
described. Satellite glial cells (SGCs) from either naïve or 10 day post-infection mice were 
digested via collagenase as previously described. Once digested, single cell TG 
suspensions were run through a 70 µM strainer, and a myelin was removed via magnetic 
cell sorting per myelin removal kit instructions (Miltenyi Biotec, CA, USA) to generate a 
purified population of SGCs [249]. Further, infected TGs were purified from infiltrating 
macrophages through magnetic cell sorting of F4/80+ cells per kit instructions (Miltenyi 
Biotec, CA, USA). Purified SGCs were then pulsed with ovalbumin232-339 (10 μg/mL) for 
30 minutes at 37°C, 5% CO2 and co-cultured with CFSE (5 μM) labeled OT-II cells for 5 
days at a 1:1 ratio (1x105 for the magnetically sorted T cell samples, 2x105 for FACs 
sorted T Cells) in a 96 well U-bottom plate at 37°C, 5% CO2. CD4 T cells from OT-II mice 
were either isolated using magnetic cell sorting as previously described, or underwent 
cell surface staining in an HBSS solution containing DNASE I (Sigma-Aldrich, MO, USA) 
before being sorted on a Sony SY3200 at the Microscopy, Imaging and Cytometry 
Resources Core at the Wayne State University School of Medicine. After stimulation, cells 






Phenol red thread test 
To measure the tear levels of mice, phenol red-treated threads which change color 
when the pH level is changed were used (Zone-Quick-1010; Shwoa Yakuhin Kako, 
Tokyo, Japan). Briefly, mice were restrained at the base of the neck, being sure not to 
touch the face or whiskers. The threads were then placed carefully on the bulbar 
conjunctiva of the lateral canthus of the mouse eye for exactly 30 seconds. Tear levels 
were then measured using millimeter scale via the absorption of tears as indicated by the 








Figure 6: Genotyping of NK1R-/- mice.Representative PCR gel demonstrating proper 
genotype of NK1R-/- mouse. All NK1R-/- mice are tail-clipped and processed for genotyping 
prior to experimentation. Bottom panels dictates the primer sequences used for genotyping. 
The sizes of the respective bands are 236 base pairs for the NK1R-/- mice as identified via 
the NK1R R2 sequence, and 369 base pairs for the C57BL/6 controls as identified via the 

















Figure 7: Mouse trigeminal ganglion dissection. Shown is the dissection of a mouse 
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Primer Forward Reverse 
gB AACGCGACGCACATCAAG CTGGTACGCGATCAGAAAGC 
LAT GGGTGGGCTCGTGTTACAG GGACGGGTAAGTAACAGAGTCT 











Antibody Fluorochrome Dilution Company 
CD8 APC 1:100 BD Biosciences 
CD8 PE-CY7 1:100 BD Biosciences 
CD4 APC 1:100 BD Biosciences 
CD4 BV605 1:100 BD Biosciences 
CD62L FITC 1:100 BD Biosciences 
CD3 BV510 1:100 BD Biosciences 
Thy1.2 PE 1:100 BD Biosciences 
CD45 PE-Cy7 1:100 BD Biosciences 
F4/80 PE 1:100 BD Biosciences 
F4/80 APC-Cy7 1:100 BioLegend 
I-Ab BV421 1:100 BD Biosciences 
I-Ab FITC 1:100 BD Biosciences 
Vβ 5.1,5.2 PE-Cy7 1:100 BioLegend 
NK1R (N-19 Clone) Unconjugated 1:100 Santa Cruz Biotech 
NK3R (NB300-201) Unconjugated 1:100 Novus Biologicals 
Donkey anti-goat Alexa 647 1:200 Life Technologies 
Donkey anti-rabbit Alexa 647 1:200 Life Technologies 
IFNγ PE 1:100 BD Biosciences 
TNFα PE-Cy7 1:100 BD Biosciences 
Glutamine Synthetase Unconjugated 1:100 Abcam 





CHAPTER 1: THE EFFECT OF NEUROKIININ RECEPTOR SIGNALING 
ON THE ESTABLISHMENT OF HSV-1 LATENCY 
 
Abstract 
Herpes simplex virus 1 is an extremely common human pathogen able to establish 
a lifelong infection in the peripheral nervous system. To date, little is known about how 
the virus is able to establish this latency in the trigeminal ganglion (TG) of infected 
individuals. In the TG, neurons produce a number of neurotrophic factors and 
neuropeptides that can affect the immune responses to infection. One of the most 
abundantly produced neuropeptides in the TG is substance P (SP). A member of the 
tachykinin peptide family, SP actions are mostly mediated through its primary tachykinin 
receptor, neurokinin receptor 1 (NK1R). Evidence indicates that the SP-NK1R interaction 
can effectively aid in the stimulation of the immune response, including in the corneal 
immune response to HSV-1 infection. Therefore, in an effort to better understand the 
latency establishment process utilized by the virus, the current study chose to focus on 
the effect of neurokinin receptor signaling. 
Through the use of an NK1R-/- mouse model and NK1R antagonist treatment in-
vivo, the current study sought to elucidate the role of neurokinin receptor signaling in the 
early stages of ocular HSV-1 infection. Here, we show that loss of NK1R signaling via 
NK1R knockout, leads to an increase in CD8 T cell IFNγ production in the draining lymph 
node (DLN), as well as an increase in CD4 and CD8 T cells in the TG at 5 days post-
infection correlating with a decrease in viral DNA found in NK1R-/- mouse TGs. 
Interestingly, NK1R antagonist treated mice did not exhibit similar changes in immune 
response to HSV-1 infection at day 5 post-infection in the DLN or TG. Here, we 





is likely due to an increased level of corneal lymphatics in uninfected NK1R-/- mice. This 
increase in lymphatics is correlated with an increased level of VEGF-C production by 
CD11b+ cells located in the limbal area of NK1R-/- corneas. We thus conclude that the 
complete loss of NK1R signaling via NK1R knockout generates a more robust immune 
cell response to ocular HSV-1 infection due to increased levels of immune cell trafficking 
to the DLN through elevated levels of lymphatic vasculature in the cornea. 
Introduction 
The tachykinin peptide family is one of the largest, most well-known, well studied 
peptide families currently found in a variety of species, including most mammals [217]. 
The primary tachykinins that have been isolated from mammalian tissue are: substance 
P (SP), neurokinin A (NKA), neurokinin B (NKB), and hemokinin-1 [217, 218].  The 
receptors for these peptides are identified as neurokinin receptors 1-3 (NK1R, NK2R, and 
NK3R), all of which are g-protein coupled receptors [218]. These neuropeptides and their 
receptors are encoded by tachykinin (Tac) genes 1-4, wherein preprotachykinin gene A 
expression leads to the production of SP and NKA, preprotachykinin B expression leads 
to the production of NKB, preprotachykinin C expression leads to hemokinin-1 production, 
and Tacr1, 2, and 3 encode NK1R, NK2R, and NK3R, respectively [218]. As a whole, 
these neuropeptides and their receptors are found throughout the mammalian system; 
from the CNS and PNS, to lymphoid tissue, the cardiovascular system and more. 
Therefore, the study of tachykinin receptors provides an excellent target for which to study 
the neuropeptide response to HSV-1 infection [217]. 
Despite the ubiquitous expression of neurokinin receptors, their response to ocular 





corneal immune response has demonstrated that SP (the primary ligand for NK1R) is a 
pro-inflammatory molecule, as corneas with a more severe immune response were found 
to have higher levels of SP [214]. This was further shown through SP antagonist, spantide 
I treatment, which reduced immune influx and the severity of infection in mouse models 
[214]. Further, in cell culture, SP was found to induce nitric oxide (NO) production in HSV 
infected macrophages [213]. Also, while the high presence of tachykinins SP and NKA in 
the TG has been widely demonstrated [147], the role of tachykinins and neurokinin 
receptors in the presence of HSV-1 infection in the TG is largely unknown. Further, little 
is understood on how the systemic immune response is affected by NK1R signaling. 
Recent work in our laboratory has indicated that lack of NK1R signaling leads to an altered 
corneal biology causing a more robust immune response and higher viral levels in 
infected corneas of NK1R-/- mice compared to C57BL/6 mice [247].  
As previously mentioned, the early immune response to HSV-1 plays a critical role 
in the establishment of the HSV-1 latent state. Concurrently, SP and the tachykinin family 
of neuropeptides have been demonstrated as effective immune system stimulators, able 
to stimulate neutrophils, macrophages, lymphocytes, natural killer cells, and DCs; all 
which have been found to express the predominant tachykinin receptor, NK1R [219]. 
While the SP response to infection has been found to be detrimental to the corneal 
response to ocular HSV-1 as the cornea is an immune privileged tissue [214]; in tissues 
where inflammation is less detrimental, SP may provide a benefit. Work focused on 
understanding the role of the SP-NK1R interaction during genital HSV-2 infection found 





SP during infection was also found to be correlated with the increased expression of LAT 
in neurons infected with HSV-1 [216].  
Therefore, the focus of the current study was to determine the importance of the 
SP-NK1R interaction during the early infection period of HSV-1. Due to the pro-
inflammatory properties of SP during inflammatory conditions, in combination with the 
increased NK1R signaling during inflammation [219], it was of interest to determine how 
this neuropeptide interaction affects the immune system both systemically (particularly in 
the draining lymph node) as well as in the TG. In particular, we sought to understand how 
NK1R signaling affected the early adaptive immune response in the lymph nodes and 
TG, and how this response affected the ability of HSV-1 to establish latency in the TG. 
Ultimately, given the reports that the SP-NK1R interaction is pro-inflammatory, we 
hypothesized that NK1R signaling was critical to the early immune response to HSV-1 
infection, and that loss of NK1R signaling would lead to a decreased immune response 
and increased level of virus establishing latency in the TG. 
Results 
Neuropeptide expression in the TG changes during ocular HSV-1 infection 
During primary ocular HSV-1 infection, the virus quickly gains access to the nerve 
endings in the cornea leading to detectable virus in the TG as early as 48-72 hours post-
infection [102]. While evidence has demonstrated that neuropeptides in the TG respond 
to stimuli such as migraine [150], little is known as to how these neuropeptides respond 
during the course of HSV-1 infection in the TG. Our data demonstrates that a number of 
the neuropeptides and neurotrophic factors present in the TG experience changes in their 





the TG vary, there is a consistent trend identifiable at day 9 post-infection. What is seen, 
is that there is a significant change from day 4 to day 9 post-infection in six of the 
neuropeptides studies, and similarly, four neuropeptides experience significant changes 
in relative mRNA expression when comparing day 9 to day 18 post-infection.  
Though many neuropeptides respond to HSV-1 infection, of interest to the current 
study was the notable changes in Tac1 expression, the gene which encodes for SP. Here, 
we see that there is a 20% increase in Tac1 expression from day 9 to days 18 and 28 
post-infection. Interestingly, the Tac1 expression is near steady state levels in all days 
studied, except at day 9 post-infection where a noticeable decrease is seen. When 
exploring the expression of tachykinin receptors NK1R, NK2R, and NK3R; the results 
show that both NK1R and NK3R are present in the corneas and TG of C57BL/6 mice 
(Figure 9A). Interestingly, though SP expresses the highest affinity for NK1R [217], NK3R 
is much more highly expressed in the TG and cornea than either NK1R or NK2R (Figure 
9A). Further, our data shows that both NK1R and NK3R mRNA expression increases 
throughout the course of HSV-1 infection in the TG (Figure 9B). Therefore, neurokinin 
signaling likely plays an important role during the establishment of HSV-1 latency in the 
TG. 
Loss of neurokinin receptor signaling leads to an increased immune response 
To determine the effect NK1R signaling has on HSV-1 establishment, both 
C57BL/6 and NK1R-/- mice on a C57BL/6 background were infected with ocular HSV-1, 
and both lymph nodes and TGs were harvested at day 5 post-infection for flow cytometry 
studies. Our results indicated a nearly 60% increase in the production of IFNγ by 





type mice, as determined via intracellular cytokine staining following SSIEFRAL 
stimulation. However, similar changes in TNFα production are not seen (Figure 10).  
When further exploring the CD4 and CD8 T cell populations in the lymph nodes of 
C57BL/6 and NK1R-/- mice, we see further indication of an increased systemic immune 
response. Flow cytometry of lymph nodes at day 5 post-infection show that there is an 
increase in proliferating CD4 and CD8 T cells as marked by Ki-67 staining (Figure 11A). 
Additionally, both proliferating T cell populations have an increased percentage of 
CD62L+ Ki-67+ cells in NK1R-/- mice compared to C57BL/6 mice (Figure 11B).  
Our results indicate similar changes in the TGs of NK1R-/- mice when compared to 
C57BL/6 mice at day 5 post-infection. Figure 12 demonstrates a nearly 2-fold increase in 
the total number of infiltrating CD45+ cells in the TG at day 5 post-infection in NK1R-/- 
mice. There is a 2.7-fold increase in both the CD4 and CD8 T cell total cell numbers in 
NK1R-/- mice as well. Further, our results indicate a nearly 2-fold decrease of viral DNA 
found in the TG of NK1R-/- mice at 10 days post-infection (Figure 20), as quantified via 
qPCR against a standard curve created from a plasmid inserted with the sequence of 
HSV-1 gB (Figure 13) [115]. Altogether, our data demonstrates that loss of NK1R 
signaling leads to a more robust immune response in the TG, a decreased viral load in 
the TG, higher virus specific cytokine production by CD8 T cells in the lymph node during 
early stage HSV-1 infection, and an increase in T cell proliferation in the lymph nodes as 
well. Lastly, NK1R-/- mouse TGs do not demonstrate differences in NK2R or NK3R 
expression due to loss of NK1R, and thus compensatory upregulation of other neurokinin 
receptors does not appear to be the cause of the changes identified at the TG of the 






NK1R-/- mice exhibit an altered corneal biology 
Our results indicating an increased systemic and TG immune response in NK1R-/- 
mice were somewhat surprising. Recent publications have indicated that NK1R is 
upregulated in inflammatory conditions [219], and concurrently, its primary ligand SP has 
been shown to increase inflammation of the corneas of HSV-1 infected mice [214]. 
However, recent work in our lab has demonstrated that NK1R-/- mice experience higher 
viral titers at early time-points post-ocular HSV-1 infection, as well as an early 
development of HSK [247]. This previous work clarifies that this outcome identified in 
NK1R-/- mice is likely due to altered corneal biology in these mice, and therefore, it was 
necessary to determine if changes in the corneas of NK1R-/- mice affect the increased 
early immune response to HSV-1 observed in this study. 
Interestingly, we found that naïve NK1R-/- mice exhibit a >2-fold increase in the 
percentage of corneal surface that is lymphatically vascularized as identified via Lyve1 
staining of corneal whole mounts (Figure 14A). This difference in lymphatic vasculature 
between wild-type and NK1R-/- mice persists at day 3 post-infection of ocular HSV-1 
infection, but by day 6 post-infection we see similar percentages of cornea covered in 
lymphatic vasculature between the two groups (Figure 14B). To understand a potential 
cause of these increased lymphatics, we utilized western blots of ocular tissue 
homogenates consisting of both the cornea, and surrounding limbal tissue to determine 
the amount of VEGF-C located in ocular tissue. VEGF-C was measured, as it has been 
identified as a precursor to lymphatic vessel formation [251]. Here, we show a modest, 





/- mice compared to wild-type mice (Figure 15A). Further, a recent publication in our lab 
has indicated an accumulation of CD11c+CD11b+ cells in the corneal limbus of NK1R-/- 
mice [247], and we indicate here via confocal microscope images of the corneal limbus 
of NK1R-/- mice, a colocalization of CD11b+ cells with VEGF-C+ cells (Figure 15B). 
Therefore, our results show that NK1R-/- mice exhibit a great increase in lymphatic 
vasculature in the cornea of uninfected mice, a condition that persists up to day 6 post-
infection. Further, our data shows that a likely cause for this increase vasculature is an 
increased amount of VEGF-C production in the ocular tissue of NK1R-/- mice, which is 
likely the product of accumulated CD11b+ cells in the corneal limbus. 
NK1R antagonist treatment does not lead to similar increases in the immune 
response to ocular HSV-1 infection 
Due to the increased immune response seen in the TG and DLN of NK1R-/- mice, 
and subsequent changes identified in the corneal biology of the knockout mice, we next 
wanted to determine if this effect could be replicated in mice treated with NK1R 
antagonist, L760735. Likewise, due to the high expression of NK3R in both the cornea 
and TG (Figure 9A), mice were treated with NK3R antagonist SB222200 as well. For 
these experiments, mice were give ocular HSV-1 infection and starting at day 0, twice 
daily intra-peritoneal injections of L760735 (.5 mg/kg) (Tocris Biosciences, MN, USA), 
SB222200 (2 mg/kg) (Tocris Biosciences, MN, USA), or a combination of both 
antagonists together were given until the day of sacrifice at day 5 post-infection. 
Interestingly, we did not see the same increase in the percentage SSIEFRAL 
stimulated CD8+IFNγ+ cells in NK1R antagonist treated mice that we observed in NK1R-





cells was not seen in NK3R antagonist treated mice, or mice treated with both 
antagonists, when compared to control treated mice. As with NK1R-/- mice, we also did 
not see a change in the production of TNFα by SSEIFARL stimulated CD8 T cells in any 
of the antagonist treated mouse groups (Figure 16B). 
Similarly, we did not see a statistically significant change in the number of CD45+, 
CD4+, or CD8+ cells infiltrating the TG at day 5 post-infection in mice treated with NK1R 
and NK3R antagonists. Again, mice were given twice daily intra-peritoneal injections of 
either NK1R antagonist, NK3R antagonist, or a combination of both as previously 
described. Both CD4 and CD8 T cell numbers were relatively unchanged in mice treated 
with NK1R antagonist, and a similar trend was observed in the other treatment groups 
(Figure 17B). However, it should be noted that while not statistically significant, we do see 
a nearly 2-fold increase in the total number of C45+ cells in NK1R antagonist treated mice 
TGs compared to control treated mice TGs (Figure 17C). In conclusion, our results show 
that mice treated with NK1R antagonist do not experience an increase in SSIEFRAL 
induced CD8 T cell cytokine production, nor did we observe an increase in the CD4 or 
CD8 T cell response in the TGs of antagonist treated mice. 
Lastly, it is important to note that while we do not see much change in NK1R 
antagonist treated mice compared to controls, we do have evidence that this particular 
NK1R antagonist (L760735) is an effective antagonist in-vivo. As shown in our lab, mice 
given twice daily intra-peritoneal injections of L760735 (.5mg/kg) experience a significant 
reduction in tear volume as measured via phenol red thread test (Figure 18). Further, 
work by Kovacs et. al. indicates that SP, as released from sensory nerves of the TG, aids 





[252]. Therefore, it is likely that this decreased tear secretion in antagonist treated mice 
is due to proper inhibition of NK1R-/- signaling, as demonstrated in the previous report. 
Discussion 
The focus of this study was to understand how neuropeptides, particularly the 
signaling of the neuropeptide SP through NK1R, is able to affect the immune response, 
and ultimately the establishment of, HSV-1 latency. Here, we show that neuropeptides in 
the TG, which contains neurons with axonal projections that innervate the cornea [220], 
have an altered expression profile in response to corneal HSV-1 infection, during which 
HSV-1 travels in a retrograde fashion from the nerve endings to the neuronal soma [17]. 
These changes in neuropeptide expression in the TG during HSV-1 infection are 
somewhat as expected. Research has shown that not only does damage to the nerve 
endings of the TG generate alterations in neuropeptide expression [150], there have also 
been findings that neuropeptides such as galanin [202, 203] and CGRP [160], among 
others, respond during HSV-1 infection. Of interest to this study, were the changes in 
Tac1 expression and SP production in the TG. The notable decrease in Tac1 mRNA at 
day 9 post-infection, as well as the increased mRNA expression of both Tacr1 and Tacr3 
in the TG, in combination with reports indicating that SP signaling through NK1R is 
associated with increases in inflammation [211, 219], led to the hypothesis prior to study 
that NK1R-/- mice would have a decreased immune response to HSV-1 infection. 
However, the results of this study indicate that NK1R-/- mouse exhibit an increased 
inflammatory profile compared to wild-type controls. 
When examining the systemic immune response to HSV-1 infection via the 





by SSIEFARL (gB) stimulated CD8 T cells. Given the strong evidence that IFNγ plays a 
key role in the induction and maintenance of HSV-1 latency [126, 253], our data indicates 
that NK1R-/- is thus beneficial to the early immune response to HSV-1. Further, evidence 
of this is seen when examining the CD4 and CD8 T cell populations in the DLN. Our 
results indicate that both CD4 and CD8 T cells proliferate more in mice that lack proper 
NK1R signaling. We also show that there is an increase in proliferating central memory T 
cells (TCM), identified through the expression of CD62L [254]. Interestingly, it was 
discovered that SP expression is able to inhibit T cell adhesion via NK1R signaling [167]. 
Thus, it appears that the decreased NK1R signaling in the knockout mice may lead to 
stronger binding and activation of T cells, ultimately leading to an increase in TCM. It is 
also possible that NK1R-/- leads to an earlier production of the TCM population, and thus it 
may be of interest to explore the progression of TCM throughout the course of ocular HSV-
1 infection.  
Similar to the results in the DLN, FACS analysis shows that there is an increased 
number CD45+ cells, CD4 T cells, and CD8 T cells in the TG of mice lacking proper NK1R 
signaling. This increase in immune response is likely to improve the establishment of 
HSV-1 latency, as the importance of both CD4 and CD8 T cells in the TG during HSV-1 
infection is well documented [106, 124]. Here, we provide evidence of this, as NK1R-/- 
mice exhibit a decreased viral load in the TG at day 10 post-infection, indicating that the 
increased immune cell influx in the TG at 5 days post-infection effectively reduced the 
replication and spread of the virus, leading to a smaller amount of viral DNA present in 





Altogether, both the systemic and the localized TG immune responses are 
increased due to the loss of NK1R signaling. However, similar results were not found 
when wild-type C57BL/6 mice were treated systemically with NK1R and NK3R 
antagonists. Systemically, we did not find a similar increase in IFNγ producing CD8 T 
cells in mice treated with NK1R antagonist, NK3R antagonist, or a combination of both. 
Similarly, we did not find a significant increase in the number of CD4 or CD8 T cells in the 
TG of all three treatment groups. Therefore, it appears that the changes in the immune 
response seen in the NK1R-/- mice are not due only to loss of NK1R signaling during HSV-
1 infection, but may also be due to changes seen at the cornea of mice that develop 
without NK1R. 
Concurrently, our lab has recently published work indicating that the corneas of 
NK1R-/- mice exhibit an earlier development of HSK and an increase in corneal DC 
infiltration compared to wild-type mice. Further, the NK1R-/- mice demonstrated a 
decreased corneal nerve density and increased number of CD11b+CD11c+ DCs in the 
limbal area [247]. Therefore, the experimental focus shifted to understanding the potential 
changes in the NK1R-/- mouse corneas. Here, we show that loss of neurokinin receptor 
signaling leads to a significant increase in the percentage of the cornea that is 
lymphatically vascularized prior to any infection, a condition that persists until day 6 post-
infection. Further, our results show that loss of NK1R signaling leads to increased VEGF-
C production in the cornea and surrounding conjunctiva, and there is a co-localization of 
VEGF-C with CD11b+ cells in the limbal area. Collectively, our data indicates that it is 





C (a known lymphangiogeneic aid [255]) as produced by a larger number of CD11b+ cells 
in the corneal limbal area of NK1R-/- mice.  
Overall, our data shows that NK1R-/- leads to a more robust immune response in 
the DLN and TG of HSV-1 infected mice. This immune response is not seen in mice 
treated with NK1R and NK3R antagonists, and thus differences at the corneal surface 
appear to be an influential cause of the increased immune response identified in NK1R-/- 
mice. Our data indicates that this increased immune response is likely due to an increased 
level of corneal lymphatics as produced by a larger number of CD11b+ cells producing 
VEGF-C. Recently, work by Gurung et. al. has shown that in response to HSV-1 infection, 
corneas displayed increased lymphangiogenesis, which when inhibited led to an 
increased viral load in the TG, and loss of HSV-1 specific CD8 T cells [256]. This report 
also found a loss of activated DCs in mice with reduced levels of lymphatics. Together, 
with the data present here, this indicates that the increased immune response identified 
in mice lacking NK1R signaling is likely due to increased antigen presentation by the DCs 
that enter the cornea, leading to a more effective activation of CD4 and CD8 T cells in the 








Figure 8: Neuropeptide and neurotrophic factor gene expression in the TG. (A) RT-qPCR 
relative mRNA expression of neuropeptides and neurotrophic factors in the TG during ocular 
HSV-1 infection. Samples are relative to naïve mRNA levels, normalized to GAPDH via the 
ΔΔCq equation. The p values were calculated using a one-way ANOVA: *p < .05. (B) RT-








Figure 9: Neurokinin receptor expression in the cornea and TG. (A) RT-qPCR mRNA 
expression of neurokinin receptors 1, 2, and 3 in the cornea and TG in naïve, 
uninfected, mice, relative to GAPDH. (B) RT-qPCR relative mRNA expression of 
neurokinin receptors 1, 2, and 3 in the TG during ocular HSV-1 infection. Samples 
represented as relative to naïve TGs, normalized to GAPDH via the ΔΔCq equation, 








Figure 10: Loss of NK1R signaling leads to increased IFNγ production at day 5 post-infection. NK1R-
/- and C57BL/6 mouse lymph nodes were collected at 5 days post-infection and lymphocytes were 
stained for intracellular cytokines after in vitro stimulation with SSIEFARL peptide (10 μg/mL). 
Representative FACS plots demonstrate the proportion of IFNγ and TNFα producing CD8 T cells 
in the lymph node. Scatter plot shows the frequency of IFNγ+ CD8+ T cells and TNFα+ CD8+ T 
cells in C57BL/6 and NK1R-/-mice. Data shown is representative of two independent experiments. 





Figure 11: NK1R-/- mice lymph nodes express an increase in actively dividing CD4 and CD8 T cells 
at 5 days post-infection. (A) Representative FACS plots demonstrate the proportion of Ki-67+ 
actively dividing CD4 and CD8 T cells, as well as actively dividing CD62L+ (central memory) T 
cells in the lymph node of C57BL/6 and NK1R-/- mice. (B) Bar graphs show the percentages of 
Ki-67+ and CD62L+ CD4 and CD8 T cells, where n = 5. Statistical analysis performed using an 





Figure 12: Loss of NK1R signaling leads to a larger T cell infiltration in the TG at day 5 post-infection.  
(A) Representative FACS plots demonstrate the proportion of infiltrating CD45+ immune cells in 
the TG of C57BL/6 and NK1R-/- mice. Scatter plots show the total CD45+ cell number in the TG. 
(B) Representative FACS plots show the proportion of CD4+ and CD8+ T cells in the TG of 
C57BL/6 and NK1R-/- mice. Scatter plots show the total CD4+ and CD8+ T cells present in the 





Figure 13: Plasmids for LAT and gB generate a standard curve to determine the 
respective copy numbers of the genes. (A) Plasmids (gifted by Dr. Homoyan 
Ghiasi) can be used to measure known copy numbers of either HSV-1 gB or LAT 
in a tissue. (B) Scatter plots demonstrate the efficacy of the assay in the TG 
wherein active virus late genes (gB) decrease over time and latent viral gene 
product (LAT) increases. Statistical analysis performed using an unpaired 





Figure 14: NK1R-/- mice corneas have altered corneal lymphatics that persists up to day 6 post-
infection. (A) Representative images of corneal whole mounts (20X magnification) taken from 
naïve C57BL/6 and NK1R-/- mice stained for Lyve1 (green). Scatter plot shows the percentage 
of the cornea lymphatically vascularized as determined through Photoshop analysis. Statistical 
analysis performed using an unpaired student t test. ***p < .001. (B) Representative images of 
corneal whole mounts (20X magnification) taken from 3 day post-infection C57BL/6 and NK1R-
/- mice stained for Lyve1 (red). Scatter plot shows the percentage of the cornea lymphatically 
vascularized during HSV-1 infection as determined through Photoshop analysis. Statistical 





Figure 15: NK1R-/- mice express higher levels of VEGF-C which co-localizes with CD11b. (A) 
Representative western blot shows VEGF-C production in naïve ocular tissue (cornea and 
limbal conjunctiva) of C57BL/6 and NK1R-/- mice. Scatter plot demonstrates the quantity of 
VEGF-C in respective mouse ocular tissue. Quantity is represented as relative to β-Actin. 
Statistical analysis performed using an unpaired student t-test. *p < .05. (B) Confocal 
microscope images of corneal whole mounts stained for CD11b (green) and VEGF-C (red). 
Images are a magnified (40X magnification) section of the corneal limbus, wherein the corneal 






Figure 16: Neurokinin receptor antagonist treatment does not affect IFNγ or TNFα production by 
CD8 T cells in the lymph node of 5 day post-infection mice. C57BL/6 mice were infected with 
ocular HSV-1 and received intra-peritoneal injections twice daily starting at day 0 of L760735 
NK1R antagonist (.5 mg/kg), SB222200 NK3R antagonist (2 mg/kg), or a combination of both 
until euthanization at day 5 post-infection. Lymph nodes were collected at 5 days post-infection 
and lymphocytes were stained for intracellular cytokines after in vitro stimulation with SSIEFARL 
peptide (10 μg/mL). (A) Representative FACS plots demonstrate the proportion of IFNγ and 
TNFα producing CD8 T cells in the lymph node of all treatment groups. (B) Scatter plot shows 
the frequency of IFNγ+ CD8+ T cells and TNFα+ CD8+ T cells in all treatment groups. Data 






Figure 17: Neurokinin receptor antagonist treatment does not affect T cell infiltration into the TG 
of 5 day post-infection mice. C57BL/6 mice were infected with ocular HSV-1 and received intra-
peritoneal injections twice daily starting at day 0 of L760735 NK1R antagonist (.5 mg/kg), 
SB222200 NK3R antagonist (2 mg/kg), or a combination of both until euthanization at day 5 
post-infection. (A) Representative FACS plots demonstrate the proportion of infiltrating CD45+ 
immune cells in the TG of all treatment groups. (B) Representative FACS plots show the 
proportion of CD4+ and CD8+ T cells in the TG of all treatment groups. (C) Scatter plots show 
the total CD45+ cells, CD8+ T cells, and CD4+ T cells in the TG at day 5 post-infection. Data 






Figure 18: L760735 treatment effectively reduces tear production in mice during HSV-1 
infection.Mouse tear production was measured using a phenol red thread test (A) wherein 
more tear production leads to larger measurable red area of the thread. (B) Scatter plot 
analysis of tear production via length of phenol red section of the thread from uninfected to 





Figure 19: Neurokinin receptor 2 and 3 expression in the NK1R-/- mice TG. 
Relative mRNA expression as detected by RT-qPCR of neurokinin 
receptors 2 and 3 in the TG of naive NK1R-/- mice. Results expressed as 
relative to naïve levels of respective neurokinin receptor mRNA levels in 






Figure 20: Loss of NK1R signaling leads to a decreased viral load in the TG at 
day 10 post-infection. TGs of both C57BL/6 and NK1R-/- mice at 10 days 
post-infection were excised and the total DNA was isolated. The viral copy 
number per TG was then measured via qPCR using a standard curve 
created from the gB plasmid. Data shown is representative of two 
independent experiments. Statistical analysis performed using an unpaired 





CHAPTER 2: THE EFFECT OF NEUROKININ RECEPTOR SIGNALING 
ON THE MAINTENANCE OF HSV-1 LATENCY 
 
Abstract 
The ability of herpes simplex virus 1 to maintain a latent viral state in the trigeminal 
ganglion (TG) is critical to both the survival of the virus, as well as the infected individual. 
Currently, the cause of viral reactivation from this latent state is unknown. While research 
has indicated that CD8 T cells play a significant role in maintaining HSV-1 latency, little 
is known about how locally produced neuropeptides in the TG affect viral latency. The 
focus of the current study revolved around the tachykinin neuropeptide substance P (SP), 
and its primary ligand, neurokinin 1 receptor (NK1R). However, SP signaling can also be 
mediated through other members of the tachykinin receptor family as well.  
The aim of this study was to elucidate the effect of neurokinin receptor signaling 
on the maintenance of HSV-1 latency in the TG. Here we show that partial loss of 
neurokinin receptor signaling effectively improves the host ability to maintain the HSV-1 
latent state. In-vivo, we found that neurokinin receptor antagonist treatment post-
establishment of HSV-1 latency did not affect the level of latency associated transcript 
(LAT) in the TG. However, NK1R-/- mice did demonstrate a significant increase in the 
number of LAT transcripts present in the TG at day 18 post-infection, and this increase in 
LAT correlated with a decrease in viral reactivation in ex-vivo TG explants, indicating that 
LAT plays a role in preventing the expression of viral genes. Similarly, we found that 
NK1R and NK3R antagonist treatment in ex-vivo TG cultures was able to delay viral 
reactivation, an effect not seen when both receptors were inhibited. Our work thus 
demonstrates that partial inhibition of neurokinin receptor signaling creates a beneficial 





neuronal TG signaling during the maintenance of HSV-1 latency that has yet to be 
discovered. 
Introduction 
Currently, the most common cause of ocular herpes infection is reactivation of 
latent virus from the TG that travels to the corneal surface [9, 257]. Unfortunately, very 
little is understood regarding the cause of reactivation, and what changes to either the 
immune system or otherwise, lead to these damaging reactivation events. Therefore, it is 
of great interest to understand how viral latency is maintained. As it stands, much of the 
focus regarding viral latency is centered on how the host immune response is able to 
control and maintain viral latency. However, the effect of neuropeptide signaling on HSV-
1 latency maintenance is not well studied. 
Regarding the role of immune cells in the maintenance of HSV-1 latency, current 
research has indicated that the primary cell type responsible for this is CD8 T cells [124]. 
However, while many studies have demonstrated the importance of the CD8 T cell 
response to HSV-1 latency maintenance [16], little is understood on how this CD8 T cell 
response may be affected by neuropeptide signaling. Given the high expression of SP in 
the TG, and the reported ability that the SP-NK1R interaction is able to regulate T cell 
functioning [209, 258], it was of interest to the current study to understand how NK1R 
signaling may affect the maintenance of HSV-1 latency in the TG. 
The balance of immune response during latent HSV-1 corneal infection is critical. 
Evidence indicates that inhibiting SP signaling during HSV-1 infection leads to a decrease 
in the corneal immune cell influx at later time-points post-ocular HSV-1 infection [214]. 
However, low levels of inflammation in the form of CD4 and CD8 T cells in the TG are 





that much of the SP in the cornea is a product of the innervating nerve fibers of neurons 
located in the TG [259], it is of interest to determine how beneficial SP-NK1R signaling is 
in the TG during HSV-1 latency, as it is damaging when expressed at the corneal surface 
during inflammatory events [214]. Interestingly, a report by Hamza et. al. indicates that 
when TG neurons are cultured, an increased level of SP was identified in neurons that 
were also positive for LAT expression [216]. This interaction, combined with the relatively 
significant presence of SP in TG neurons provides great opportunity for SP to affect the 
host response to the maintenance of HSV-1 latency. Therefore, it appears that the 
neurokinin receptor signaling in the TG is beneficial to the immune cells in the TG during 
HSV-1 latency. We hypothesize that neurokinin receptor signaling aids the host response 
to latent HSV-1 infection and therefore improves the maintenance of HSV-1 latency. 
Results 
Latent transcripts are increased in NK1R-/- mouse TGs 
Due to the notable changes identified in the early immune response to HSV-1 in 
the TG of NK1R-/- mice, this aim focused on understanding the effect NK1R-/- has on the 
maintenance of HSV-1 latency, and thus our initial study focused on determining if there 
is a change in latent virus in the TG between knockout and wild-type mice. To properly 
determine the presence of latent virus in the TG, the most effective measure is to quantify 
the level of LAT within the TG of latently infected mice [260]. This can be done using 
plasmids that contain a sequence of LAT or gB [115, 261] (generously donated by Dr. 
Homayon Ghiasi); because these plasmids are of known size, we can quantitate the 
relative copy number of either transcript and generate a standard curve by which we can 





Therefore, both NK1R-/- and C57BL/6 mice were ocularly infected with HSV-1, and 
the virus was allowed to reach a fully latent state at day 18 post-infection. At this time, 
TGs were removed, and the LAT copy number was determined via RT-qPCR against a 
standard curve generated from plasmids containing the LAT gene. Our results (Figure 
21) show that NK1R-/- mouse TGs contain over twice as many copies of LAT at day 18 
post-infection than wild-type mice.  
Loss of neurokinin receptor signaling is unable to affect the maintenance of HSV-
1 latency in the TG in-vivo 
Due to the increased level of LAT identified in NK1R-/- mice, we next wanted to 
determine how this increased LAT may affect viral reactivation from latency. Therefore, 
to properly determine how NK1R signaling affects the maintenance of viral latency after 
latency has already been established, latently infected mice (day 18 post-infection) were 
treated with NK1R and NK3R antagonists. Similar to the methodology used in Chapter 1, 
C57BL/6 mice at 18 days post-infection, were treated twice daily with NK1R and NK3R 
antagonists for 10 days. At day 28 post-infection, mice were sacrificed, and TGs were 
measured for LAT copy number (Figure 22). Our results indicated that treatment with 
either antagonist individually, or a combination of both, was unable to generate detectable 
changes in LAT copy number. Also, RT-qPCR was conducted for the detection of 
immediate early protein ICP0, which is often used as an indicator for viral reactivation 
[38]. However, there were no detectable levels of ICP0 in the TG of antagonist treated 
mice (data not shown).Together this data indicates that it is unlikely that inhibition of 
neurokinin receptor signaling altered the maintenance of HSV-1 latency through the 





Ex-vivo reactivation is delayed in TGs treated with NK1R or NK3R antagonists 
To further understand the effect of neurokinin receptor signaling on HSV-1 
reactivation, an ex-vivo culture model can be used, wherein latently infected TGs are 
excised from mice and placed into culture. Once in culture, the virus will spontaneously 
reactivate, and active virus will be found in the culture medium. Therefore, media taken 
from the TG culture can be placed on a monolayer of VERO cells, wherein active virus 
can be identified by phenotypic changes in these VERO cells, primarily the rounding and 
detachment of cells from the plate surface (Figure 23).  
When latently infected TGs of 18-day post-infection mice were placed into culture 
medium containing NK1R antagonist L760735 at 10 µM, a statistically significant delay in 
the number of days that virus took to reactivate was found (Figure 24A). Similarly, a delay 
in viral reactivation was identified when TG culture medium was supplemented with 1 µM 
NK3R antagonist (Figure 24B). Interestingly, when latently infected TGs were placed in 
medium containing both NK1R and NK3R antagonist, there was no change in the date at 
which virus spontaneously reactivated (Figure 24C). 
Further, when we looked at the level of LAT in the TG of C57BL/6 vs NK1R-/-, we 
found a greater than 2-fold increase in LAT copy number in the NK1R-/- mice (Figure 21). 
Therefore, we utilized ex-vivo reactivation cultures to identify how this difference in LAT 
expression may change the ability of the virus to maintain latency between the two 
groups. Our data shows, that similar to NK1R antagonist treated TGs, NK1R-/- TGs 
demonstrate a delay in viral reactivation, wherein NK1R-/- TGs exhibited active virus in 
the supernatant of ex-vivo cultures a day later than C57BL/6 mice (Figure 25A). Further, 





exhibit changes in viral reactivation from NK1R-/- control TGs (Figure 25B). Lastly, to 
determine if increased SP signaling has an effect on viral maintenance, ex-vivo cultures 
of latently infected TGs were placed in media containing SP agonist GR73632. Our 
results show that SP agonism did not affect the rate at which virus reactivated from the 
TG, relative to the control group (Figure 26). Overall, this data demonstrates that while 
single inhibition of either NK1R or NK3R was effective in increasing the maintenance of 
HSV-1 latency as identified through the delay in viral reactivation, inhibition of both 
neurokinin receptors or the addition of SP agonist was unable to induce changes in viral 
latency maintenance.  
Discussion 
While currently very little is understood about the maintenance of HSV-1 latency, 
a number of factors have been identified for the reactivation of latent HSV-1. In mouse 
models, hyperthermic stress [91], restraint stress [125], and ultraviolet light exposure 
[262] have been utilized to induce reactivation in-vivo. However, these studies have been 
unable to identify the critical changes in either the immune system or in the peripheral 
nervous system that occurs leading to reactivation of the virus. Despite evidence that 
neuropeptides respond to primary HSV-1 infection, very little is understood as to how they 
may play a role in the maintenance of HSV-1 latency. Therefore, in concurrence with the 
findings in Chapter 1 that neurokinin receptor signaling may play a role in the 
establishment of HSV-1 latency, it was of great interest to understand how neurokinin 
receptor signaling affects the maintenance of HSV-1 latency. 
To date, little is understood about how neurokinin receptor signaling affects HSV-





neurons harvest from the TGs of rats displayed a higher number of LAT+ neurons in HSV-
1 infected cultures treated with SP [216]. This indicates that presence of LAT may lead to 
increased production of SP by LAT+ neurons, increasing viral latency. Further, research 
involving chemical sympathectomy indicates that mice that receive sympathectomy 
treatment exhibit increased mortality to HSV-1 infection, in combination with an increase 
in SP levels in the TG. This work also indicates that mice treated with NK1R antagonist 
demonstrated an increase survival compared to control groups [215]. Similarly, our work 
also found that mice with reduced neurokinin receptor signaling demonstrate decreased 
viral reactivation. Together, this evidence indicates that neurokinin receptor signaling 
plays a significant role in the maintenance of HSV-1 latency.  
Using an ex-vivo model to study viral reactivation. Our results found that in TG 
cultures treated with either NK1R antagonist or NK3R antagonist, there was a delay in 
viral reactivation. Interestingly, in latent TG cultures treated with both NK1R and NK3R 
antagonist, we did not see the same delay in viral reactivation. Our results indicate a 
similar result in ex-vivo reactivation cultures of TGs taken from NK1R-/- mice. Here, we 
show that like NK1R antagonist treated TGs, the TGs of NK1R-/- mice display an increase 
in the number of days in which actively replicating virus becomes detectable in culture; a 
delay in reactivation which is not seen when NK1R-/- TGs were cultured in media 
containing an NK3R antagonist.  
It is also noteworthy that the TGs of NK1R-/- mice show an increase in LAT copy 
number by day 18 post-infection compared to control mice. This result is in agreement 
with our previous findings which showed that NK1R-/- mice have a decreased viral load in 





number in the TG is not an effective measure of the viral load at latent time points, rather, 
viral reactivation is more positively correlated with the amount of viral genome presented 
at late time-points post infection [90]. Further, LAT expression has been shown to 
decrease viral reactivation and prevent HSV-1 genome expression. Also, increased LAT 
expression is found to correlate with a decrease in HSV-1 genome present in the TG 
[263]. In agreement with the reported findings, we found that in NK1R-/- leads to increased 
LAT corresponding with decreased gB copy numbers. This indicates that the increased 
immune response observed at 5 days post-infection (Chapter 1) effectively induces 
increased latency in NK1R-/- mice. This increased latency, as marked by the higher levels 
of LAT in the TG of NK1R-/- mice, is the likely cause of the delayed reactivation seen in 
latently infected NK1R-/- TG explants, as LAT functions to suppress HSV-1 gene 
expression [263]. 
Together, our data indicates an interesting role for neurokinin receptor signaling 
during the maintenance phase of HSV-1 latency. Our results show that a partial 
impairment of neurokinin receptor signaling through blockade of either NK1R or NK3R is 
more effective at preventing viral reactivation; a result which is not seen when both 
receptors are active. This indicates a delicate balance in neurokinin receptor signaling. 
This finding is in agreement with the work previously mentioned in which NK1R antagonist 
allowed for increased survival in mice whom otherwise displayed higher levels of mortality 
due to chemical sympathectomy treatment [215]. Interestingly, this contradicts the 
hypothesis that pro-inflammatory SP signaling would aid in the immune response to HSV-






This is particularly interesting due to the effect that stress has on viral reactivation. 
During stress, SP has been found to be increased in the central nervous system [264]. 
Further, SP has been found to play a prominent role in migraine induced inflammation 
and pain, which is a common outcome of stress [265]. As indicated, both hyperthermic 
induced stress as well as restraint and social stress leads to viral reactivation in mouse 
models [125, 266], and it is therefore a possibility that stress induced increases in SP lead 
to reactivation of HSV-1 in the TG. However, it is yet unclear whether the inhibition of 
NK1R in the mouse model during HSV-1 latency has a direct effect on the inflammatory 
response in the TG at latent time-points, despite reports that NK1R is found prominently 
expressed on a number of immune cells [218]. Also, we are currently unable to identify 
the possible role that NK1R signaling may have on the neuronal functioning, which can 
play a role in HSV-1 latency as well [267]. The potential of neurokinin receptor signaling 
affecting the functioning of the TG is even more prominent when we focus on NK3R, as 
NK3R is predominantly associated with neurons in the central and peripheral nervous 
system [218]. Therefore, given that our results show similar delays in reactivation in TG 
cultures supplemented with either NK1R or NK3R antagonists, it is possible that SP 
signaling in the TG not only affects the immune system, but may be preventing viral 
reactivation through yet undiscovered modulation of neuronal functioning and thus the 
HSV-1 LAT present in the infected neurons as well. 
Despite the changes identified ex-vivo, the current study was unable to fully 
elucidate the effect of neurokinin receptor signaling in-vivo. Our results indicate that in 
latently infected mice, treatment with neurokinin receptor antagonists was unable to 





that would indicate deviations in viral reactivation. However, given that the ex-vivo results 
demonstrate a beneficial effect of inhibited neurokinin receptor signaling, these results 
are as expected. Rather, to more properly understand the potential beneficial effects of 
NK1R and NK3R inhibition, a mouse model utilizing inducible reactivation (such as that 
through UV-B exposure or restraint stress), would be more beneficial. During in-vivo 
induced reactivation, we would expect a greater decrease in LAT and a greater increase 
in ICP0 in control treated mice, compared to those mice treated with neurokinin receptor 
antagonists. Lastly, it is important to note that while NK1R signaling is inhibited in NK1R-
/- and antagonist treated mice, SP is still present in the system. Therefore, future studies 
utilizing SP depletion, such as using PPTA-/- mice which lack SP, may be able to further 
elucidate the importance of the SP-NK1R interaction during the maintenance phase of 
the HSV-1 life cycle. 
In summary, this data shows that neurokinin receptor signaling is partially 
beneficial to the maintenance of HSV-1 latency. While a complete inhibition of NK1R and 
NK3R signaling was unable to aid viral latency, singular inhibition of only one of NK1R or 
NK3R proved to be beneficial to the maintenance of HSV-1 latency.  Further, our data 
indicates that loss of NK1R signaling during the establishment of HSV-1 leads to an 
increased level of LAT, which may aid in preventing viral reactivation [263]. Due to the 
substantial expression of SP in neurons of the TG [147], it is likely that much of the 
neurokinin receptor signaling in the TG is mediated through SP. Thus, our data indicates 
that a moderate level of SP signaling is more beneficial for the control of HSV-1 







Figure 21: Loss of NK1R signaling increases the amount of LAT present in the 
TG at day 18 post-infection. Scatter plot shows the LAT copy numbers of  
NK1R-/- mice and C57BL/6 mice at day 18 post-infection, as run against a 
plasmid generated standard curve for LAT. Data shown is representative of 
two independent experiments. Statistical analysis performed using an 





Figure 22: NK1R antagonist treatment in latently infected mice did not produce 
significant changes in LAT copy numbers in the TG. C57BL/6 mice were infected 
with ocular HSV-1 and the virus was allowed to establish latency in the TG at 18 
days post-infection. Starting at day 18, mice received intra-peritoneal injections 
twice daily of L760735 NK1R antagonist (.5 mg/kg), SB222200 NK3R antagonist 
(2 mg/kg), or a combination of both until euthanization at day 28 post-infection. 
At day 28, TGs of the mice were excised for RT-qPCR analysis against a 
plasmid generated standard curve for LAT. Statistical analysis performed using 





Figure 23: Phenotypic changes in VERO cells are used to identify the presence of 
replicating virus in viral reactivation assays. Representative images show VERO 
cells in 24 well plates (10X magnification) prior to the presence of replicating virus 
(uninfected) and after the appearance of replicating virus (infected). When the 
media of an excised latently infected TG is placed in a well containing a monolayer 
of VERO cells, the day of reactivation is marked by phenotypic changes indicating 





Figure 24: NK1R antagonist L760735 and NK3R antagonist SB222200 individually delay viral 
reactivation in ex-vivo TG cultures. TGs at 18 days post-infection were excised and placed 
in to individual wells of a 24 well plate containing media supplemented with NK1R 
antagonist, NK3R antagonist, or both together. Daily, 200 µL of media was removed, placed 
on a monolayer of VERO cells and monitored for reactivation. The earliest day of 
reactivation was recorded. (A) Culture media supplemented with NK1R antagonist, (B) 
culture media supplemented with NK3R antagonist, and (C) culture media supplemented 
with 10 µM NK1R and NK3R antagonist. Statistical analysis performed using an unpaired 





Figure 25: The TGs of latently infected NK1R-/- mice experience delayed viral 
reactivation that does not occur if NK3R antagonist is present in culture media. TGs at 
18 days post-infection were excised and placed in to individual wells of a 24 well plate. 
Daily, 200 µL of media was removed, placed on a monolayer of VERO cells and 
monitored for reactivation. The earliest day of reactivation was recorded. (A) Data 
from TG cultures of NK1R-/- vs C57BL/6 mice. (B) Data from TG cultures of NK1R-/- 
mice with or without NK3R antagonist at 10μM. Statistical analysis performed using 






Figure 26: NK1R agonist GR73632 treatment does not lead to a change in 
viral reactivation rates in ex-vivo viral reactivation assays. TGs at 18 days 
post-infection were excised and placed in to individual wells of a 24 well 
plate and supplemented with NK1R agonist GR73632. Daily, 200 µL of 
media was removed, placed on a monolayer of VERO cells, and 
monitored for reactivation. Statistical analysis performed using an 





CHAPTER 3: THE ROLE OF SATELITE GLIAL CELLS IN THE 
MAINTENANCE OF HSV-1 LATENCY 
 
Abstract 
The ability of herpes simplex virus 1 to maintain a latent, non-infectious state in the 
trigeminal ganglion (TG) is currently not well understood. The TG, or fifth cranial nerve, is 
a peripheral nervous tissue that consists of neurons and surrounding satellite glial cells. 
However, upon infection, HSV-1 will establish a lifelong latent infection in only the 
neurons. The role satellite glial cells (SGCs) have during HSV-1 infection is not well 
understood, as much of the research regarding the maintenance of HSV-1 latency has 
focused on the immune response in the TG. Therefore, the aim of this study was to 
determine the extent by which SGCs are able to affect the maintenance of HSV-1 latency. 
Our study found that SGCs respond to early HSV-1 infection through proliferation 
occurring at day 10 post-infection. While much of the virus has been cleared from the TG 
at this time-point, we propose that this proliferation aids not only in the containment of 
viral spread in the TG, but may also be a response to SGC cell death during early HSV-
1 infection. Further, we found that SGCs express a number of immune cell markers during 
HSV-1 infection, including MHC-II expression. We therefore hypothesized that SGCs 
have the ability to act as an antigen presenting cell. Through co-cultures of SGCs and 
OVA specific T cells, we were able to show for the first time, that SGCs are capable of 
acting as an antigen presenting cell to CD4 T cells. We thus propose that during latent 
HSV-1 infection, SGCs are able to present antigen and stimulate the CD4 T cell 








HSV-1 infection, while certainly able to alter the peptide expression in the TG, also 
shows evidence of affecting localized TG cell function. For example, satellite glial cells 
(SGCs), due to close interaction with surrounding neurons, will become infected during 
reactivation and primary infection [80]. Concurrently, HSV-1 infection in TG cultures was 
found to increase calcium signaling between neurons and surrounding SGCs as well as 
increase fusion of SGCs with neurons [80]. HSV-1 has also been demonstrated to affect 
gene expression in latently infected neurons, most of which were upregulated genes 
involved in signaling such as Stat1, g-protein receptor family genes, and the potassium 
voltage-gated gene Shaw 1 [268]. In neuron enriched cultures, the Socs3 gene was 
upregulated, implicating that this neuronal gene expression change is induced by the 
virus to inhibit the immune response [267]. In a general HSV infection model of the DRG, 
it was found that infection led to an increase in the number of SGCs almost 2 fold over 
injury alone [222]. This increase may inhibit the spread of HSV-1 to other neurons as 
demonstrated in cultures of SGCs [223]. All of this evidence suggests that SGCs may 
have a number of yet to be discovered roles regarding HSV-1 infection in the TG. 
As previously discussed, it is well known that the immune system, particularly CD8 
T cells, CD4 T cells, macrophages, and dendritic cells (DCs) are critical in the host 
immune response to HSV-1 in the TG. Despite the wealth of knowledge and research in 
this area, very little is known about the effect that the local cell environment of the TG has 
on latency. While previous studies have indicated that SGCs appear to have a 
proliferative response to HSV-1 infection [222-224], the importance of this proliferation 





indicates that SGCs express a variety of immune cell markers such as pan-leukocyte 
marker CD45, leukocyte marker CD11b, and the leukocyte adhesion protein ICAM-1 [240, 
269]. This finding is particularly interesting, as little is understood regarding the ability of 
T cells to remain active during latent HSV-1 infection, preventing viral spread and 
reactivation [112, 120, 124].  
While the early immune response and activation of T cells revolves around antigen 
presentation by macrophages and DCs [114, 115, 270], very little is understood about 
antigen presentation during latent infection. Currently, the only evidence that there may 
be antigen presenting cells present in latently infected TGs, is a study regarding a specific 
subset of DCs, known as CD8α+ DCs, that may be able to act as an APC during latent 
HSV-1 infection [114, 115]. The importance of the immune response to maintain viral 
latency cannot be overstated, as it is the reactivation events from latency that lead not 
only to corneal inflammation and blindness [2], but they can also lead to death caused by 
untreated HSV-1 infection in the brain leading to herpes simplex encephalitis [138]. 
Therefore, the focus of the current study was to understand the role of SGCs during the 
maintenance of HSV-1 latency. 
As previously stated, the indication that SGCs not only proliferate in response to 
HSV-1, but that these cells also express immune cell markers often associated with 
antigen presenting cells is of particular interest to our study. While the primary role of 
SGCs in the peripheral nervous tissue is to provide structural support to neurons [221] 
and recycle the neuronal signaling byproduct glutamate to glutamine through the enzyme 
glutamine synthetase (GS) [226], we sought to determine if SGCs may play a significant 





to determine how the SGCs respond to HSV-1 infection in the mouse model, and whether 
or not they also express immune cell markers. Further, we sought to determine whether 
the expression of these immune cell markers provided a functional significance to SGCs 
during HSV-1 infection. Here, we hypothesize that SGCs do express an APC like 
phenotype during HSV-1 infection, and this expression allows for SGCs to act as a non-
professional APC, capable of presenting antigen to T cells present in the TG. 
Results 
SGCs proliferate in response to HSV-1 infection and express immune cell markers 
Though evidence indicates that SGCs respond to HSV-1 infection [222], and in 
humans SGCs have been shown to express a number of markers associated with 
immune cells [240], little is truly understood about how the SGCs may affect the ability of 
HSV-1 to establish and maintain latency in the TG. To better understand how SGCs may 
proliferate in response to HSV-1, TGs taken from mice at 5 and 10 days post-infection 
were stained for FACS with Ki-67 to indicate dividing cells (Figure 27A). Our results show 
that there are two actively dividing cell populations in an infected TG; a population 
expressing CD11b at a high level (CD11bhigh) and a population that is glutamine 
synthetase (GS) positive and CD11b low expressing (GS+ CD11bLow). Further, we found 
that the while the percentage of cells that are dividing in TGs at 5 vs 10 days post-infection 
are similar (Figure 27B), there is a noticeable shift in which cell types are dividing from 
day 5 to 10 post-infection. Here, we show that at day 5 post-infection, nearly 75% of the 
Ki-67+ cells in the TG are CD11bhigh expressing myeloid cells, while only 25% are GS+ 





at the Ki-67+ population at day 10 post-infection, wherein 74% of dividing cells are GS+ 
CD11bLow and only 24% are CD11bhigh expressing (Figure 27C). 
To further understand how the SGCs are responding to HSV-1 infection, we 
examined the expression of immune cell markers CD45, I-Ab (MHC-II marker), and F4/80 
by the CD11bhigh and GS+CD11bLow populations we found to proliferate during HSV-1 
infection. Our results show that when gating for CD11b and GS expression, we see three 
distinct cell populations. As Figure 28 shows, we not only see the same CD11b 
expressing populations as before, but also a population that is both GS and CD11b 
negative. When measuring the mean fluorescence intensity (MFI) of CD45, I-Ab, and 
F4/80 in the three cell populations, there is a notable change in MFI that exists between 
the three populations (Figure 27B). Here, we see very high MFIs for all three immune cell 
markers at both 5 and 10 days post-infection, including MFIs greater than 20,000 for both 
CD45 and I-Ab for the CD11bHigh population. The MFIs for all three populations greatly 
decrease in the CD11bLow population with an MFI near 330 for CD45 and 2,200 for I-Ab 
at day 5 post-infection, and similar numbers are seen at day 10 post-infection. However, 
the MFIs are even lower in the CD11b negative population, where we see MFIs of just 35 
and 650 for CD45 and I-Ab respectively; a nearly 10-fold drop in MFI expression from the 
CD11blow population. Overall, this data demonstrates that SGCs both proliferate in 
response to HSV-1 infection in the mouse model, and the SGCs exhibit a distinct immune 
cell profile, expressing immune cell markers CD11b, CD45, I-Ab, and F4/80 at markedly 
lower levels than the infiltrating myeloid population, yet higher levels than those cells 






Removal of myelin allows for the generation of clean populations of SGCs 
To properly understand how SGCs are able to stimulate and present antigen to T 
cells, it was necessary to obtain a clean population of SGCs. The primary cause of 
potential obstruction to SGC-T cell interaction in culture is the myelin debris generated 
when peripheral nerve tissue is cleaved during the collagenase treatment required to 
create a single cell suspension. To do this, a myelin removal kit (Miltenyi Biotec) was used 
to magnetically separate the myelin from the cells in the TG [249]. Shown in Figure 29A, 
are representative images of TGs placed in culture when myelin removal has been done. 
Similarly, Figure 29B is a representative image of TG samples that have undergone 
myelin removal and run for flow cytometry. Both culture images and FACS plots show the 
effectiveness of myelin removal, as clean populations of SGCs are easily identified. The 
phenotype of the isolated cell population is further confirmed when FACS staining is 
conducted on TGs where myelin removal was conducted, As Figure 30 demonstrates a 
clear population of GS+ CD11bLow cells is identified in myelin removed TGs.  
SGCs display a relatively low expression of neurokinin receptors 
The previous aims focused on the effect that neurokinin receptor signaling has on 
the establishment and maintenance of HSV-1 latency in the TG, and thus it was of interest 
to examine the expression of both NK1R and NK3R in the TG. As demonstrated 
previously, NK1R and NK3R are both produced in the TG as measured via RT-qPCR 
(Figure 9A). Here, we demonstrate that there are two populations of cells that express 
NK1R and NK3R through flow cytometry. The representative FACs plots in Figure 31A, 
show that NK3R is primarily expressed in a cell population that is both FSC and SSC 





higher levels in both the higher (8768 MFI) and lower expressing subsets (767 MFI) than 
the similar higher (MFI 3101) and lower (77 MFI) NK3R expressing subsets of the SGC 
population, which has a low SSC and FSC. This can be seen with the MFIs of NK1R on 
both cell populations as well, as the neuron subsets express NK1R MFI at twice the levels 
of the respective MFIs of the SGC population subsets (Figure 31B). Overall, this data 
illustrates that while SGCs do appear to express neurokinin receptors 1 and 3 at low 
levels, the primary cell type for neurokinin signaling is neurons. 
SGCs are able to stimulate the proliferation of T cells in-vivo 
While we demonstrate that SGCs do express immune cell markers, it has yet to 
be determined as to what extent this expression allows the SGCs to act in a similar 
fashion to immune cells, particularly, as an antigen presenting cell (APC). Here, we 
demonstrate confocal microscope data that indicates the presence of both CD4 and CD8 
T cells in latently infected TGs (Figure 32). Therefore, given the expression of MHC-II 
identified on the SGCs, we sought to determine if SGCs could act as an APC to CD4 T 
cells. To determine this, an assay was standardized by which the APC ability of a cell is 
measured via the proliferation of T cells. To standardize this assay, a dendritic cell line, 
DC2.4 (Millipore Sigma), was irradiated and co-cultured with magnetically isolated CD4+ 
T cells labeled with CFSE from OT-II mouse spleens. Briefly, DC2.4 cells were pulsed 
with 10 µg/mL ovalbumin323-339 (OVA323-339) peptide and co-cultured with the OT-II mouse 
CD4 T cells specific for the OVA antigen at a ratio of 1:10. Representative FACS plots of 
the cultures illustrates a decrease in CFSE MFI in a subset of CD4High expressing cells 
as the OVA323-339 concentration is increased (Figure 33A). The data shows, that there is 





>2-fold increase from 1 to 10 µg OVA treated groups. Further, when the CFSE MFI is 
measured in the CD4High population, a 2-fold decrease in CFSE MFI occurs when OVA 
concentration is increased from 0.1 to 10 µg/mL (Figure 33B). This indicates, as expected, 
that DC2.4 cells are able to act as an APC, presenting antigen to CD4 T cells, leading to 
their proliferation as marked by an increased number of CD4High expressing cells and 
decreased CFSE expression.  
Due to the effectiveness of this assay, it was then performed utilizing SGCs in 
place of the DC2.4 cells. SGCs from both naïve and 10-day post-infection mice were 
purified using the myelin removal method previously demonstrated (Figure 29). Further, 
as there were likely to be infiltrating F4/80+ macrophages in the infected TGs at day 10 
post-infection [102, 270], magnetic cell separation was performed on SGCs to remove 
potential non-SGC induced antigen presentation (Figure 34). In the culture, our 
representative images demonstrate the presence of CD4 blast cells (circled cells), which 
are larger in size, in the well of co-cultured infected SGCs with peptide. These blast cells 
are not found to be present when no-peptide is added (Figure 35A). The presence of 
these blast cells indicates the proliferation of CD4 T cells due to the presentation of the 
OVA323-339 antigen [271]. Further, representative FACS plots (Figure 35B), demonstrate 
a distinct population of OVA specific CD4High expressing cells (identified as Vβ5.1,5.2+ 
(Figure 36)) which display a decrease in CFSE MFI in both the naïve and infected SGC 
cultures compared to the T cell only control cultures (Figure 35B). The FACS data 
demonstrates a nearly identical number of CD4High cells in both SGC cultures; a count 
which is a modest, but noticeable, 17% increase from the T cell only controls (Figure 





little decrease seen from the T cell only control to the uninfected SGC culture (Figure 
35C); but there is a nearly 25% decrease in CFSE MFI when comparing the naïve SGC 
culture to the T cell only culture (Figure 35C).  
While the evidence presented is very encouraging, the number of CD4High cells in 
the T cell only controls was very interesting. Therefore, it was necessary to determine the 
purity of the magnetically sorted CD4+ T cells. As shown in the representative FACS plot 
in Figure 37, 10% of the lymphocyte population is positive for MHC-II expression, and we 
obtained a T cell purity of just 77% when CD4 T cells were isolated magnetically. 
Therefore, it is possible that the presence of I-Ab+ antigen presenting cells is the cause 
of antigen presentation and proliferation of T cells identified in the T cell only control 
group.  
Thus, a second method of FACS cell sorting was utilized to generate a more pure 
(95%) CD4 T cell population from the OT-II mice (Figure 38B). SGCs where then isolated 
from 10-day post-infection mice as previously described, and co-cultured with the sorted 
CD4 T cells for 5 days. Our results show, that when SGCs are co-cultured with CD4 T 
cells in the presence of OVA323-339, there is a nearly 70% reduction in the CD4High CFSE 
MFI between the SGC co-cultured group and the T cell only group; and a 60% reduction 
in CD4High CFSE MFI between the IL-2 treated groups. Further, the representative FACs 
plots (Figure 38C) of the CD4High CFSE MFI demonstrate a significant increase in the 
number of cellular divisions, as represented by the distinct peaks in CFSE expression. 
Our results show that the SGC co-culture groups display up to five cellular divisions, while 
the T cell control culture treated with IL-2 showed just two peaks, and the T cell only 





SGC co-cultures are over 2-fold greater than their respective T cell only controls (Figure 
38D). Lastly, we see no difference in the CFSE MFI or CD4High cell counts if SGC:T cell 
co-cultures are treated with or without IL-2, though the T cell only cultures did exhibit a  
25% decrease in CFSE MFI when treated with IL-2 (Figure 38D). Altogether, this data 
demonstrates that ovalbumin stimulated CD4 T cells of OT-II transgenic mice are able to 
be stimulated by APCs in culture, and we show that SGCs are able to stimulate OVA 
specific CD4 T cell proliferation when OVA antigen is present in culture, and thus SGCs 
are effectively acting as an APC. 
Discussion 
Due to the high prevalence of HSV-1 in the general population [272], the virus 
remains a consistent health threat. Unfortunately, current research has been unable to 
identify both the cause, and the mechanism by which the virus reactivates from the latent 
state. As HSV-1 is spread very easily due to continued presence of latent virus in the 
peripheral nervous system [2], it is of great importance to understand the mechanism by 
which an infected individual is able to maintain the virus in its latent state, and thus prevent 
the spread of reactivated replicating virus. Currently, much of the focus on understanding 
viral reactivation has concentrated around the immune response [96], while very little 
emphasis has been placed on understanding the role of resident peripheral nerve cells. 
Here, we show that the resident population of satellite glial cells in the TG not only 
respond to infection, but we also demonstrate a potential mechanism by which they may 






While research has shown that SGCs in humans exhibit an immune cell-like 
phenotype post-mortem [240], it is unclear as to how SGCs respond during the course of 
HSV-1 infection. Therefore, we sought to understand how SGCs act in response to the 
virus entering the TG and ultimately affect the establishment latency. Previous research 
has indicated that SGCs proliferate early after HSV flank infection [222], and therefore 
flow cytometry staining with Ki-67 was used. Here, we show that there are two distinct 
populations of dividing cells as the virus enters the TG and begins to establish latency. 
Our results indicate that at 5 days post-infection, a large majority of the dividing cells 
highly express CD11b, a myeloid cell marker, indicating that these cells are likely 
infiltrating immune cells. However, at day 10 post-infection, a majority of the dividing cells 
do not express CD11b at a high level. Further, these CD11b low expressing cells are 
glutamine synthetase (GS) positive (a key enzyme marker for SGCs [249]).  
These results indicate that the GS+CD11bLow population are likely SGCs, and SGC 
proliferation takes place after much of the replicating virus has been removed by from the 
TG by the adaptive immune response [102]. While other studies have hypothesized that 
SGC proliferation in response to HSV-1 infection serves to prevent the spread of virus 
from one neuron to the next [221, 222] – effectively limiting the number of neurons the 
virus is able infect and establish latency in – our results suggest that proliferation may 
serve other purposes as well. One potential cause for viral proliferation after viral 
clearance may be due to SGCs that become infected when actively replicating virus is 
present in the peripheral nervous system, and undergo apoptosis in response to this 
infection [273]. Therefore, it is possible that the increased proliferation noted at day 10 





viral replication. Future study focused on more extensive kinetics of SGCs during the 
establishment of HSV-1 latency may provide more clarity on the effect of SGC 
proliferation, however, there are limited means by which researches can control the 
replication of SGCs in the TG, and therefore any future studies in this area will likely 
require new experimental techniques not yet available. 
Currently, we have also found that SGCs not only respond to infection through 
proliferation, but they also express a distinct immune cell profile that suggests they may 
be able to perform immune cell-like functions. Through flow cytometry, we have identified 
three cell populations in the TG during infection. Through CD11b and GS expression, we 
were able to identify that SGCs express immune cell markers CD45, I-Ab, and F4/80 
(Figure 28). While the SGC population did not express any of these markers at MFIs at 
the same level as traditional immune cells (CD11bHigh expression), they did express all 
three of these markers at a MFIs greater than the GS negative, CD11b negative 
population. Therefore, it was of interest to the current study to determine if the expression 
of these immune cell markers by SGCS enabled them to act in a fashion similar to immune 
cells, particularly, in the presentation of antigen to T cells. 
To explore the potential that SGCs can act as an APC, we established a protocol 
using professional APCs, dendritic cells, to determine the extent to which antigen 
presentation could lead to T cell proliferation as measured by CFSE. To ensure that 
antigen presentation would take place, the CD4 T cells of OT-II transgenic mice were 
used, as these T cells have been genetically modified to express T cell receptors specific 
for the OVA323-339 peptide antigen as presented by MHC-II [274]. Here, we demonstrate 





co-cultured with DCs underwent increased proliferation in response to increased 
concentrations of antigen. In particular, we identified a specific subset of CD4 T cells that 
were larger in size and more highly expressed CD4. This subset of cells, identified as 
CD4High, is likely to be proliferating lymphoblast cells, as identified through the decrease 
in CFSE expression and the increased size. 
 Next, it was necessary to develop a method by which a clean population of SGCs 
could be isolated from the TG, absent of the myelin debris that is produced during the 
generation of single cell suspensions from nervous tissue and may impact the ability of 
SGCs to interact with CD4 T cells in culture [249]. Here, we demonstrate that the magnetic 
removal of myelin effectively produces a clean population of SGCs (Figure 29) that will 
allow for the proper interaction between SGCs and T cells in culture. Therefore, SGC 
populations from naïve and 10-day post-infected mice were co-cultured with OVA specific 
CD4 T cells in the presence of OVA323-339 peptide isolated through magnetic cell sorting. 
Through CFSE labeling, we demonstrate a modest decrease in CFSE signaling combined 
with a moderate increase in a subset of T cells that more highly express CD4 and 
Vβ5.1,5.2 (CD4High subset). However, the amount to which T cell proliferation was 
identified in the T cell only controls was unexpected, and examination of the purity of 
magnetically separated CD4 T cells from OT-II indicates, a small, but not insignificant 
percentage of MHC-II positive cells, indicating that our T cell only control cultures likely 
contain APCs that led to the proliferation identified. 
Therefore, a more effective method for CD4 T cell isolation was required. Utilizing 
FACS sorting (Figure 38B), we were able to generate a far purer population of CD4 T 





proved far more effective in the co-culture studies. Here, we demonstrate that SGCs are 
in fact able to stimulate the proliferation of CD4 T cells through MHC-II antigen 
presentation. Our results show a marked decrease in CFSE labeling in concurrence with 
notable increases in the number of cell divisions. The data clearly shows an increase in 
CD4 T cell proliferation and an increase in the number of CD4High cells as well. 
Interestingly, IL-2 supplementation did not affect T cell proliferation in SGC co-cultures. 
However, the IL-2 did effectively produce proliferation in the T cell only controls as 
expected [275].  
Ultimately, our data shows that SGCs not only divide in response to HSV-1 
infection, but they also demonstrate a distinct immune cell profile. Further, we illustrate 
that this immune cell profile, particularly the expression of MHC-II, allows for ability of 
SGCs to act as a non-professional APC. We clearly show that SGCs stimulated with 
peptide presented through MHC-II can activate CD4 T cells. Given that there is a number 
of CD4 T cells present in the latent TG (Figure 32), this indicates a yet undiscovered role 
for SGCs during the maintenance of HSV-1 latency. While previous research has 
indicated that CD4 T cells play a significant role in early viral clearance from the TG [276], 
there is little indication of the role that CD4 T cells have in the maintenance of HSV-1 
latency [112]. Here, however, we indicate a mechanism by which SGCs are able to 
stimulate CD4 T cells, and thus potentially aid in the maintenance of HSV-1 latency. As 
shown in Figure 39, this SGC-T cell stimulation may lead to an increase in inflammatory 
cytokines such as IL-2, TNFα, and IFNγ, which are crucial to the maintenance of HSV-1 
latency in the TG [126, 277]. While SGCs do become infected during the early stages of 





of latency in these cells. Therefore, it is likely that viral peptide is received by the SGCs 
via the significant number of gap junctions between SGCs and the neurons they surround 
[221, 227]. It is also possible that the SGCs may be able to aid the stimulation of CD8 T 
cells through MHC-I antigen presentation, and future studies may be conducted utilizing 
virus specific T cells to determine this potential role. 
Finally, it was of interest to identify how the current study on SGCs may relate to 
the previous aims focused on the role of neurokinin receptors in HSV-1 latency. Here, we 
find that SGCs do in fact express both NK1R and NK3R, though this expression is 
relatively low compared to that expressed by neurons (Figure 31). Further, our data 
indicates a higher expression of NK3R in the TG compared to NK1R, which is in 
agreement with previous research [218]. Therefore, any effect of neurokinin receptor 
signaling on the maintenance of HSV-1 latency is most likely mediated via changes in 
neurons. However, this does not eliminate a potential role for neurokinin receptor 
signaling affecting the activity of SGCs. Rather, it remains possible that the downstream 
effects of neurokinin receptor signaling in the neuron can have a significant impact on the 
activity of SGCs, and thus alter any potential activity (such as antigen presentation) that 









Figure 27: There are two actively dividing cell populations in HSV-1 infected TGs. (A) 
Representative FACS plots demonstrating the proportion of actively dividing cells (Ki-67+) 
and two populations of Ki-67+ cells were identified via CD11b and GS expression (B) Scatter 
plot analysis of the total percentage of cell population of the gated populations. (C) Scatter 
plot analysis of the Ki-67+ cell populations. Statistical analysis performed using an unpaired 





Figure 28: Satellite glial cells exhibit a distinct immune cell profile. (A) Representative 
FACS plots of TGs at 5 and 10 days post-infection. Staining indicates three cell 
populations wherein (1) represents myeloid cells, (2) represents SGCs, and (3) 
represents all other cell types and myelin debris. (B) Representative FACS plots of the 
mean fluorescence intensity (MFI) of antigen presenting cell markers CD45, IA-b (MHC-





Figure 29: Removal of myelin allows for the generation of a clean satellite glial cell 
population. (A) Phase contrast microscope images demonstrating the effect of myelin 
removal (10X magnification). * represent neurons and arrows represent SGCs (B) 
Representative FACS plots demonstrating the effect of the removal of myelin on flow 





Figure 30: SGC population in myelin removed TGs. Representative FACs plot demonstrating 
the satellite glial cell population gate (left panel) and subsequent expression of glutamine 
synthetase (GS) (middle panel), as well as demonstrating the GS+ CD11bMed expression of 






Figure 31: Satellite glial cells express NK3R and NK1R at lower levels than neurons in naïve 
TGs. FACS of naïve TGs, that underwent myelin removal. Population 1 represents low FSC-
A SSC-A SGCs, while the high SSC-A FSC-A of population 2 is likely neurons. Histogram 
plots normalized to the mode demonstrate two peaks for both populations when stained with 










Figure 32: CD4 and CD8 T cells are present in the TG of latently infected mice. Confocal 
microscope image at 40X magnification demonstrates the presence of CD4 (red) and CD8 






Figure 33: Ovalbumin specific T cells can be stimulated in-vivo with an antigen 
presenting cell. Irradiated DC2.4 dendritic cells pulsed with 10 µg/mL ovalbumin323-
339 peptide for 30 minutes were co-cultured at a 1:10 ratio with MACS sorted CD4+ 
T cells from OT-II mouse spleens labeled with CFSE for 4 days. (A) Representative 
FACS plots demonstrate the gating strategy, wherein the MFI of CFSE is measured 
in the CD4high and CD4low populations. (B) Scatter plots demonstrate the CFSE MFI 
of the CD4high population in all three groups, as well as the total number of cells in 
the CD4high population in all three groups. Statistical analysis performed using a 








Figure 34: Magnetic removal of F4/80+ cells in infected TGs. Infected TGs at 10 days post-
infection were excised, pooled, and myelin was removed. TG suspensions were then 





Figure 35: Satellite glial cells are able to stimulate T cell proliferation. Naïve and 10 days post-
infection TGs from C57BL/6 mice were purified of myelin, infected TGs were further purified to 
remove infiltrating F4/80+ cells due to infection, and SGCs were pulsed with 10 µg/mL 
ovalbumin323-339 peptide for 30 minutes were co-cultured at a ratio of 1:1 with MACS sorted 
CD4+ T cells from OT-II mouse spleens labeled with CFSE for 5 days at an equivalent of 1 TG 
per well. (A) Representative images of the SGCs from infected mice co-cultured OT-II T cells 
show that when peptide is added, there is a noticeable presence of actively dividing blast cells 
(white circles) indicative of antigen presentation and T cell activation. (B) Representative FACS 
plots demonstrate the gating strategy, wherein the MFI of CFSE is measured in the CD4high and 
CD4low populations of T cells specific to ovalbumin323-339 via Vβ5.1,5.2. (B) Scatter plots 
demonstrate the CFSE MFI of the CD4high population in all three groups, as well as the total 
number of cells in the CD4high population in all three groups. Statistical analysis performed using 





Figure 36: Antibody Vβ 5.1, 5.2 identifies ovalbumin specific T cells. Representative FACS 
plots demonstrating that the CD4 T cells isolated from the spleens of OT-II transgenic 






Figure 37: Magnetic CD4 T cell separation contains antigen presenting cells. FACS plots 
demonstrating the purity of CD4 T cells isolated from magnetic cell sorting. All percentages 
listed are of the lymphocyte gate in the left panel. Presence of I-Ab indicates cells that have 





Figure 38: Satellite glial cells can act as an antigen presenting cell and induce T cell proliferation. 
10 days post-infection TGs from C57BL/6 mice were purified of myelin, and infiltrating F4/80+ 
cells were magnetically sorted out. SGCs were pulsed with 10 µg/mL ovalbumin323-339 peptide 
for 30 minutes and co-cultured at a ratio of 1:1 with FACs sorted CD4+ T cells from OT-II 
mouse spleens labeled with CFSE for 5 days at an equivalent of 1 TG per well. Further, 50 U 
IL-2 was added to half the wells. (A) Representative images of either SGCs (top) or T cells 
only (bottom) in culture show actively dividing blast cells (white circles) indicative of antigen 
presentation and T cell activation are present in only the SGC wells. (B) Representative FACS 
plot demonstrating the purity of FACs sorted T cells prior to culture. (C) Representative FACS 
plots demonstrate the CFSE MFI of both the CD4high and CD4low populations of T cells specific 
to OVA323-339. (D) Scatter plots demonstrate the CFSE MFI of the CD4high population in all four 
groups, as well as the total number of cells in the CD4high population in all four groups. 






Figure 39: Proposed mechanism of antigen presentation by SGCs. Artist 
interpretation of the antigen presentation by SGCs to CD4 T cells leading to the 






The continued survival of herpes simplex virus 1 (HSV-1) is heavily reliant on the 
virus’ ability to establish a life-long latent infection. As it infects over half of the world’s 
population, HSV-1 is one of the most common viruses in the world. Ultimately, the virus’ 
ability to forever maintain its presence in the peripheral nervous system serves as a great 
advantage for the overall survival of the virus. Through reactivation events, the virus is 
able to easily spread from person to person, most often through the saliva. However, due 
to the health burden created via reactivation events that lead to viral infection of the 
cornea and central nervous, it is great importance to understand the mechanisms by 
which the virus is able to establish and maintain this latent state. In this work we focus on 
defining a role in which neurokinin receptors are able affect the virus’ ability to both 
establish and maintain latency, as well as characterize the role of satellite glial cells 
(SGCs) during HSV-1 latency. 
To explore the effects of neurokinin receptors on the establishment of HSV-1 
latency, experimental methods utilizing both NK1R-/- mice, and NK1R antagonist treated 
mice were used. Interestingly, we found that while the inhibition of NK1R during the 
establishment phase of HSV-1 latency did not lead to changes in either the systemic or 
trigeminal ganglion (TG) immune response; mice with absent NK1R signaling from birth 
did. Our results demonstrated that complete loss of NK1R signaling led to an increase in 
immune response systemically and in the TG, and also resulted in a diminished level of 
viral DNA in the TG. We further indicate that this increased immune response is likely due 
to an amplified level of lymphatic vasculature in the corneas of NK1R-/- mice, leading to 





Regarding the maintenance of HSV-1 latency, we show that both neurokinin 
receptor signaling and SGCs play a significant role. First, we show that loss of NK1R 
during the establishment phase leads to an increase in the amount of latency associated 
transcript (LAT) in the TG. We further conclude, that this increased level of LAT is the 
likely cause of delayed reactivation seen in NK1R-/- mouse ex-vivo TG explants. Our 
results also show that inhibition of either NK1R or NK3R individually is able to delay viral 
reactivation as well. Together, this indicates that mediated neurokinin receptor signaling 
likely plays a yet undefined role in the modulation of neuronal signaling that can greatly 
affect the maintenance of HSV-1 latency. Lastly, we demonstrate that SGCs are able to 
act as an antigen presenting cell, leading to the activation of CD4 T cells. From this 
finding, we conclude that during latent HSV-1 infection, SGCs are able to provide a 
consistent stimulus to CD4 T cells present in the TG. This stimulus is likely to lead to CD4 
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The ability of herpes simplex virus 1 (HSV-1) to establish a lifelong infection in 
neurons of the trigeminal ganglion (TG) make it a constant public health threat. Viral 
reactivation from its latent state is currently the leading cause of viral induced blindness 
in the United States, as well as the leading cause of herpes simplex encephalitis. 
Unfortunately, how the virus is able to both establish and maintain its latent state in the 
TG is not well understood. The purpose of this work was to better understand how 
neuropeptide signaling through neurokinin receptors, as well as how satellite glial cells 
(SGCs) in the TG, affect the establishment and maintenance of HSV-1 latency.  
Our results demonstrate that loss of NK1R-/- signaling in the mouse model leads 
to an increase in corneal lymphatics, which was found to correlate to increased levels of 
IFNγ produced by CD8 T cells of the draining lymph node (DLN) and increased T cell 
response in the TG. This increase in immune response was associated with a decrease 
in viral DNA in the TG during HSV-1 latency establishment. However, the changes in 





maintenance of HSV-1 latency, our work found that NK1R-/- led to increased levels of 
latency associated transcript in the TGs of latently infected mice, which correlated with a 
decrease in viral reactivation. Similar decreases in viral reactivation were identified in 
NK1R and NK3R antagonist treated mice, but no changes in viral reactivation were 
detected when both receptors were inhibited. We therefore conclude that partial loss of 
neurokinin receptor signaling in the TG is beneficial to the maintenance of the HSV-1 
latent state.  
Lastly, our work focused on understanding the role of SGCs during the 
maintenance of HSV-1 latency. We demonstrate that when cultured in the presence of 
antigenic peptide, SGCs are able to present antigen to CD4 T cells, leading to their 
proliferation. We thus describe for the first time that SGCs are able to function as a non-
professional antigen presenting cell. We therefore conclude that during latent HSV-1 
infection, SGCs are capable of stimulating CD4 T cells in the TG, leading to an 
upregulation of inflammatory cytokines that aid in the host response to maintain HSV-1 
latency. In total, this work demonstrates that the localized cellular response in the TG 
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